WO2011011789A1 - Methods and compositions for treating neuronal damage or degeneration - Google Patents
Methods and compositions for treating neuronal damage or degeneration Download PDFInfo
- Publication number
- WO2011011789A1 WO2011011789A1 PCT/US2010/043256 US2010043256W WO2011011789A1 WO 2011011789 A1 WO2011011789 A1 WO 2011011789A1 US 2010043256 W US2010043256 W US 2010043256W WO 2011011789 A1 WO2011011789 A1 WO 2011011789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding
- antibody
- sulfate
- chondroitin
- binding agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 120
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 58
- 230000003961 neuronal insult Effects 0.000 title abstract description 4
- 230000001404 mediated effect Effects 0.000 claims abstract description 50
- 230000005764 inhibitory process Effects 0.000 claims abstract description 30
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims abstract description 24
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims abstract description 24
- 230000007514 neuronal growth Effects 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 158
- 230000027455 binding Effects 0.000 claims description 127
- 239000011230 binding agent Substances 0.000 claims description 110
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 92
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 92
- 108090000623 proteins and genes Proteins 0.000 claims description 91
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 230000011664 signaling Effects 0.000 claims description 51
- 230000014511 neuron projection development Effects 0.000 claims description 39
- 210000002569 neuron Anatomy 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 208000014674 injury Diseases 0.000 claims description 28
- 208000027418 Wounds and injury Diseases 0.000 claims description 25
- 210000000020 growth cone Anatomy 0.000 claims description 23
- 230000006378 damage Effects 0.000 claims description 22
- 230000001737 promoting effect Effects 0.000 claims description 20
- 230000009689 neuronal regeneration Effects 0.000 claims description 18
- 108010077641 Nogo Proteins Proteins 0.000 claims description 15
- 102000010410 Nogo Proteins Human genes 0.000 claims description 15
- 102000001301 EGF receptor Human genes 0.000 claims description 14
- 108060006698 EGF receptor Proteins 0.000 claims description 14
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims description 13
- 101150111584 RHOA gene Proteins 0.000 claims description 13
- 230000001747 exhibiting effect Effects 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- 208000028389 Nerve injury Diseases 0.000 claims description 12
- 102000012803 ephrin Human genes 0.000 claims description 12
- 108060002566 ephrin Proteins 0.000 claims description 12
- 230000008764 nerve damage Effects 0.000 claims description 12
- 230000001537 neural effect Effects 0.000 claims description 12
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 10
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 10
- 238000000159 protein binding assay Methods 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000003923 Protein Kinase C Human genes 0.000 claims description 8
- 108090000315 Protein Kinase C Proteins 0.000 claims description 8
- 102100033940 Ephrin-A3 Human genes 0.000 claims description 7
- 108010043940 Ephrin-A3 Proteins 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 208000020431 spinal cord injury Diseases 0.000 claims description 7
- 208000030768 Optic nerve injury Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000003137 locomotive effect Effects 0.000 claims description 5
- 230000002232 neuromuscular Effects 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000002744 extracellular matrix Anatomy 0.000 claims description 4
- 230000010807 negative regulation of binding Effects 0.000 claims description 4
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 4
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 4
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 claims description 3
- 101000898647 Homo sapiens Ephrin type-A receptor 4 Proteins 0.000 claims description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims 2
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 claims 2
- 101100027996 Mus musculus Omg gene Proteins 0.000 claims 2
- 101710093481 Reticulon-4 receptor Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 20
- 229920001282 polysaccharide Polymers 0.000 description 76
- 239000005017 polysaccharide Substances 0.000 description 76
- 150000004676 glycans Chemical class 0.000 description 69
- 101000912181 Arabidopsis thaliana Cysteine synthase, mitochondrial Proteins 0.000 description 57
- CCPHAMSKHBDMDS-UHFFFAOYSA-N Chetoseminudin B Natural products C=1NC2=CC=CC=C2C=1CC1(SC)NC(=O)C(CO)(SC)N(C)C1=O CCPHAMSKHBDMDS-UHFFFAOYSA-N 0.000 description 57
- 101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 49
- DZRJLJPPUJADOO-UHFFFAOYSA-N chaetomin Natural products CN1C(=O)C2(Cc3cn(C)c4ccccc34)SSC1(CO)C(=O)N2C56CC78SSC(CO)(N(C)C7=O)C(=O)N8C5Nc9ccccc69 DZRJLJPPUJADOO-UHFFFAOYSA-N 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 49
- 241000282414 Homo sapiens Species 0.000 description 47
- 238000003556 assay Methods 0.000 description 44
- 102000005781 Nogo Receptor Human genes 0.000 description 39
- 108020003872 Nogo receptor Proteins 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 34
- 239000000427 antigen Substances 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 102000036639 antigens Human genes 0.000 description 31
- 210000003050 axon Anatomy 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 239000012634 fragment Substances 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 150000001720 carbohydrates Chemical class 0.000 description 23
- 235000014633 carbohydrates Nutrition 0.000 description 23
- 239000013604 expression vector Substances 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 230000003902 lesion Effects 0.000 description 21
- -1 CS polysaccharides Chemical class 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000002493 microarray Methods 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 230000019635 sulfation Effects 0.000 description 20
- 238000005670 sulfation reaction Methods 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 238000011069 regeneration method Methods 0.000 description 19
- 108091008815 Eph receptors Proteins 0.000 description 18
- 108010055179 EphA4 Receptor Proteins 0.000 description 17
- 102000021727 EphA4 Receptor Human genes 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 102000050554 Eph Family Receptors Human genes 0.000 description 16
- 108020004459 Small interfering RNA Proteins 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 230000008929 regeneration Effects 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 102000016611 Proteoglycans Human genes 0.000 description 14
- 108010067787 Proteoglycans Proteins 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 13
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 201000000050 myeloid neoplasm Diseases 0.000 description 12
- 210000005036 nerve Anatomy 0.000 description 12
- 210000001328 optic nerve Anatomy 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 12
- 241000283707 Capra Species 0.000 description 11
- 229920002971 Heparan sulfate Polymers 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 210000003594 spinal ganglia Anatomy 0.000 description 11
- 150000004044 tetrasaccharides Chemical class 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000001543 one-way ANOVA Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 9
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 229920000550 glycopolymer Polymers 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 8
- 229920002683 Glycosaminoglycan Polymers 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- 150000002016 disaccharides Chemical class 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229930040373 Paraformaldehyde Natural products 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000001744 histochemical effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229920002866 paraformaldehyde Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- 210000003994 retinal ganglion cell Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 229920002567 Chondroitin Polymers 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 206010056677 Nerve degeneration Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000010379 pull-down assay Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920000045 Dermatan sulfate Polymers 0.000 description 5
- 108010044085 Ephrin-B3 Proteins 0.000 description 5
- 102100023733 Ephrin-B3 Human genes 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 5
- 229940051593 dermatan sulfate Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000003522 neurite outgrowth assay Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108010052946 Activin Receptors Proteins 0.000 description 4
- 102000018918 Activin Receptors Human genes 0.000 description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108010034634 Repressor Proteins Proteins 0.000 description 4
- 102000009661 Repressor Proteins Human genes 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 4
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000009537 cortical lesion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002804 pyramidal tract Anatomy 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 239000011435 rock Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 3
- 101800001318 Capsid protein VP4 Proteins 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 241001492222 Epicoccum Species 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100026106 Probable guanine nucleotide exchange factor MCF2L2 Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 108010051423 streptavidin-agarose Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 208000025962 Crush injury Diseases 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100021811 E3 ubiquitin-protein ligase RNF5 Human genes 0.000 description 2
- 108010055196 EphA2 Receptor Proteins 0.000 description 2
- 108010055191 EphA3 Receptor Proteins 0.000 description 2
- 108010055182 EphA5 Receptor Proteins 0.000 description 2
- 108010055207 EphA6 Receptor Proteins 0.000 description 2
- 108010055153 EphA7 Receptor Proteins 0.000 description 2
- 108010055155 EphA8 Receptor Proteins 0.000 description 2
- 108010055334 EphB2 Receptor Proteins 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 2
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 2
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 2
- 102100033919 Ephrin-A2 Human genes 0.000 description 2
- 108010043942 Ephrin-A2 Proteins 0.000 description 2
- 102100033942 Ephrin-A4 Human genes 0.000 description 2
- 108010043938 Ephrin-A4 Proteins 0.000 description 2
- 102100033941 Ephrin-A5 Human genes 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 2
- 101000925251 Homo sapiens Ephrin-A5 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 239000012825 JNK inhibitor Substances 0.000 description 2
- 229940118135 JNK inhibitor Drugs 0.000 description 2
- 229920000288 Keratan sulfate Polymers 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 108091077621 MAPRE family Proteins 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 101150046281 NIP4-1 gene Proteins 0.000 description 2
- 108010043296 Neurocan Proteins 0.000 description 2
- 102100030466 Neurocan core protein Human genes 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Ornithine Chemical compound NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000001435 Synapsin Human genes 0.000 description 2
- 108050009621 Synapsin Proteins 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 1
- 102000000563 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- AAZMHPMNAVEBRE-SDBHATRESA-N 8-(4-chlorophenylthio)-cAMP Chemical compound N=1C=2C(N)=NC=NC=2N([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=1SC1=CC=C(Cl)C=C1 AAZMHPMNAVEBRE-SDBHATRESA-N 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 108010032947 Ataxin-3 Proteins 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100035682 Axin-1 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010085074 Brevican Proteins 0.000 description 1
- 102100032312 Brevican core protein Human genes 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010044213 Class 5 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000056118 Ephrin receptor family Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101150014889 Gad1 gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102100032558 Glypican-2 Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000874566 Homo sapiens Axin-1 Proteins 0.000 description 1
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 description 1
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 1
- 101000727477 Homo sapiens Reticulon-4 receptor Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000145847 Moria Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000011830 Neural cell adhesion Human genes 0.000 description 1
- 108050002172 Neural cell adhesion Proteins 0.000 description 1
- 206010052057 Neuroborreliosis Diseases 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 102100032062 Neurogenic differentiation factor 2 Human genes 0.000 description 1
- 108050000625 Neurogenic differentiation factor 2 Proteins 0.000 description 1
- 102100038554 Neurogenin-2 Human genes 0.000 description 1
- 101710096140 Neurogenin-2 Proteins 0.000 description 1
- 102100028762 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102100028492 Neuropilin-2 Human genes 0.000 description 1
- 108090000770 Neuropilin-2 Proteins 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 102000004590 Peripherins Human genes 0.000 description 1
- 108010003081 Peripherins Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 108700037966 Protein jagged-1 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101001014666 Rattus norvegicus Glypican-2 Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100028508 Receptor-type tyrosine-protein phosphatase zeta Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000043322 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 102100035124 Rhotekin Human genes 0.000 description 1
- 101710122991 Rhotekin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241000235005 Schwanniomyces occidentalis var. occidentalis Species 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 102100032795 Semaphorin-6A Human genes 0.000 description 1
- 101710199479 Semaphorin-6A Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 102100028898 Striatin Human genes 0.000 description 1
- 101710175524 Striatin Proteins 0.000 description 1
- 229930189942 Striatin Natural products 0.000 description 1
- 208000005716 Subacute Combined Degeneration Diseases 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001634922 Tausonia pullulans Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000002453 autonomic neuron Anatomy 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 210000001084 basket cell Anatomy 0.000 description 1
- 229940105596 baytril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001052 bipolar neuron Anatomy 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- NARWYSCMDPLCIQ-UHFFFAOYSA-N ethane;hydrochloride Chemical compound Cl.CC NARWYSCMDPLCIQ-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000052073 human NGFR Human genes 0.000 description 1
- 102000048720 human RTN4R Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003078 multipolar neuron Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003458 notochord Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 210000005047 peripherin Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008014 pharmaceutical binder Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- MVDHBKXZWUGLAH-UHFFFAOYSA-N striatine Natural products CC(=CCc1c(O)ccc2C3COc4cc(O)c(cc4C3Oc12)C(C)(C)C=C)C MVDHBKXZWUGLAH-UHFFFAOYSA-N 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003242 unipolar neuron Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention addresses the need for alternative treatments for neuronal damage and other neurodegenerative diseases existing in the art.
- the present invention provides a method for promoting neuronal regeneration in a subject in need thereof.
- the method comprises administering to said subject a pharmaceutical composition comprising a physiologically acceptable carrier and an agent that inhibits chondroitin sulfate E (CS-E) mediated signaling.
- the agent used in the subject method is typically present in an amount effective in promoting neurite outgrowth in said subject.
- the pharmaceutical composition administered to said subject comprises a chondroitin sulfate E (CS-E) binding agent.
- the method comprises inhibiting CS-E mediated signaling, wherein said signaling comprises intracellular signaling mediated by one or more cellular proteins selected from signaling molecules including but not limited to mitogen activated protein kinase kinase (MEK), epidermal growth factor receptor (EGFR), protein kinase C (PKC), rho kinase (RhoK), and RhoA.
- MEK mitogen activated protein kinase kinase
- EGFR epidermal growth factor receptor
- PLC protein kinase C
- RhoK rho kinase
- RhoA RhoA
- the present invention provides a method of treating a subject suffering from a neural injury comprising administering to said subject in need thereof a pharmaceutical composition comprising therapeutically effective amount of a chondroitin sulfate E (CS-E) binding agent and a physiologically acceptable carrier.
- a pharmaceutical composition comprising therapeutically effective amount of a chondroitin sulfate E (CS-E) binding agent and a physiologically acceptable carrier.
- CS-E chondroitin sulfate E
- the present invention provides a method of reducing chondroitin proteoglycan (CSPG)-mediated inhibition of neuronal growth.
- the method typically comprises: contacting a biological sample comprising one or more extracellular matrix components with a chondroitin sulfate E (CS-E) binding agent under conditions sufficient to reduce CS-E mediated signaling in said neuronal cell.
- CS-E chondroitin sulfate E
- the methods of the present invention provide for administering chondroitin sulfate E (CS-E) binding agents that are antibodies that selectively bind to CS-E.
- CS-E chondroitin sulfate E
- the antibodies may be polyclonal or monoclonal, or a fragment thereof.
- the methods of the present invention provide for administering chondroitin sulfate E (CS-E) binding agents that are soluble proteins and can selectively bind CS- E.
- the soluble proteins are comprised of soluble domains of one or more of p75 NTR , NgR, Nogo, OMgp, Ephrin receptor B3, Ephrin A3, Ephrin receptor A4, Ephrin Bl, which selectively bind to CS-E.
- the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that inhibits CS-E signaling.
- CS-E chondroitin sulfate E
- Inhibition of CS-E signaling is evidenced by, e.g., reduction of RhoA activation by CS-E in a neuronal cell or any cell expressing p75 NTR , or reduction of binding of CS-E to a surface of a neuronal cell or a cell expressing p75 NTR .
- the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that inhibits CS-E mediated growth cone collapse.
- CS-E chondroitin sulfate E
- the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that promotes neurite outgrowth in vitro.
- the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that exhibits a strong binding affinity for CS-E (e.g., a Kd value less than about 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1 ⁇ M, or 1 mM) as ascertained in an in vitro binding assay.
- the binding assay may be a surface plasmon resonance assay, such as in Example 9.
- the present invention provides for administering a chondroitin sulfate E (CS-E) binding agent that promotes or improves locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in a subject.
- CS-E chondroitin sulfate E
- the subject may be suffering from spinal cord injury, optical nerve injury, motor nerve injury, stroke, a neurodegenerative disease, or a combination thereof.
- the present invention provides a pharmaceutical composition comprising a chondroitin sulfate E (CS-E) binding agent and a physiologically acceptable carrier.
- the chondroitin sulfate E (CS-E) binding agent is an antibody exhibiting binding selectively to CS-E.
- the chondroitin sulfate E (CS-E) binding agent is a monoclonal antibody exhibiting binding selectively to CS-E.
- the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E.
- the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of NgR that selectively binds to CS-E.
- the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of p75 NTR that selectively binds to CS-E.
- the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of Nogo, OMgp, or Ephrin receptor B3 (EphB3), Ephrin A3 (Efn A3), Ephrin receptor A4 (EphA4), Ephrin Bl (Efn Bl) that selectively binds to CS-E.
- the chondroitin sulfate E (CS-E) binding agent inhibits CS-E signaling as evidenced by inhibition of RhoA activation in a neuronal cell or a cell expressing p75 NTR , or inhibition of binding of CS-E to a surface of a neuronal cell or a cell expressing p75 NTR .
- the chondroitin sulfate E (CS-E) binding agent promotes neurite outgrowth in vitro, or improves locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in a subject.
- Figure 1 depicts CS polysaccharides composed of units of the repeating disaccharide D-glucuronic acid (GIcA) and iV-acetyl-D-galactosamine (GaINAc).
- the sugar hydroxyls are variably sulfated to give rise to diverse sulfation patterns.
- Chemical structures of major sulfation motifs found in the mammalian nervous system CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-E (GlcA-4S, 6SGaINAc).
- Figure 2 shows that the CS-E sulfation motif inhibits DRG neurite outgrowth and induces growth cone collapse.
- CS-E-enriched polysaccharides repel axon crossing in a boundary assay.
- Polysaccharides (1 mg/ml) or PBS control are mixed with Texas Red and spotted on P-Orn coated coverslips.
- FIG. 4 illustrates that CS-E interacts with NgR and may require p75 NTR to inhibit neurite outgrowth.
- Figure 5 illustrates that the CS-E-specific antibody blocks CSPG-mediated growth inhibition and promotes optic nerve regeneration in vivo.
- A Anti-CS-E antibody, but not anti-CS-A or IgG control antibody, reverses inhibition of neurite outgrowth mediated by CSPGs. Dissociated chick E7 DRGs are cultured on a substratum of P-Orn (control; black) or CSPGs (0.5 ⁇ g/ml; grey or blue) in the presence of the indicated antibodies (0.1 mg/ml) for 12 hr. Treatment with each antibody alone (black bars) has no effect on neurite outgrowth relative to untreated neurons cultured on P-Orn.
- CPT-cAMP 8-(4-chlorophenylthio)-cyclic AMP
- Figure 6 illustrates that polysaccharides enriched in the CS-E sulfation motif (-60% CS-E content), but not CS-A or CS-C, inhibit the neurite outgrowth of cerebellar granule neurons (CGNs).
- CGNs cerebellar granule neurons
- Figure 8 illustrates that the anti-CS-E antibody binds selectively to a pure, synthetic CS-E tetrasaccharide and CS-E-enriched polysaccharides, whereas it does not bind to CS-A or CS-C tetrasaccharides or polysaccharides.
- A Tetrasaccharides containing pure CS-A, CS-C or CS-E motifs are conjugated to bovine serum albumin (BSA) and spotted on nitrocellulose membranes at the indicated amounts. Binding of the antibody to the membrane is detected using a goat anti-mouse secondary antibody conjugated to Alexa Fluor ® 680 and imaged using an Odyssey Infrared Imaging System.
- Figure 9 depicts the results of kinetic analysis of the interaction between the anti-CS-E antibody and CS-E tetrasaccharide by surface plasmon resonance.
- A The synthetic CS-E tetrasaccharide is covalently immobilized onto the surface via reductive amination chemistry. Binding kinetics are monitored at 25 0 C by injecting the CS-E antibody over the surface for 300 s at 30 ⁇ L-min "1 and recording the dissociation for 900 s. The surface is regenerated with 6 M guanidine HCl. The resulting sensorgrams are fit to the bivalent analyte model.
- a surface-bound analyte can bind another ligand molecule with the free binding site.
- the kinetic parameters of the fit, with standard errors in parenthesis, are tabulated in (C).
- the affinity is also measured by injecting the antibody over the surface for 3600 s to give sufficient time to reach equilibrium. The response at equilibrium is plotted versus concentration to give a K D value of 4.3 nM.
- Figure 10 illustrates that the Fc domain and the axon guidance receptor EphB2 do not bind to CS-E polysaccharides on carbohydrate microarrays.
- 10(A) depicts the binding of NgR-Fc to the array.
- 10(B) depicts the control Fc, which does not exhibit binding to the arrays.
- EphB2-Fc does not bind to glycosaminoglycans on carbohydrate microarrays. Each bar represents an average of 10 spots from one typical array. Relative binding is plotted by comparison to the fluorescence intensity of NgR-Fc binding to 5 ⁇ M CS-E.
- Figure 12 depicts the results of binding specificity of tested molecules to CS-E containing microarray.
- A EphB3-Fc binds to CS-E with high specificity by microarray analysis.
- B No binding to CS-E, nor any other glycosaminoglycan tested in A was detected for EphB2-Fc (data not shown).
- C Surface plasmon resonance of EphB3-Fc binding to CS-E polysaccharide. Data show binding at the following concentrations: 3072, 1536, 768, 384, 192, 96, 48, 24, 12, 6, 3 nM.
- D A comparison of EphB3-Fc and EphB2-Fc binding to CS-E by SPR.
- EphB3 While high concentrations of EphB3 gives a strong response by SPR (black, 3 ⁇ M; red, 1.5 ⁇ M), EphB2 shows no binding to CS-E at these concentrations.
- E Tabulation of the binding rate constants of the EphB3-Fc/CS-E interaction.
- F Full-length EphB3 is pulled down by CS-E, but not CS-C, as shown on an immunoblot.
- Figure 14 illustrates data from an oligosaccharide microarray experiment for detection and analysis of chondroitin sulfate binding agents. The results demonstrate that under the conditions tested, Nogo-66 (top panel), the amino terminal domain of Nogo (middle panel), and oligodendrocyte myelin protein (OMgp) (bottom panel) bind to CS-E polysaccharides. Nogo and OMgp have been implicated in inhibiting neuronal growth after injury.
- Figure 15 illustrates data from carbohydrate microarray and surface plasmon resonance analyses for the binding of Ephrin receptors to CS-E polysaccharides and other glycosaminoglycans.
- EphAl, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7 and EphA8 are examined for interactions with Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 ⁇ M.
- Results demonstrate variance among Ephrin receptor species for specific binding to CS-E-enriched polysaccharides.
- Figure 16 illustrates data from carbohydrate microarray and surface plasmon resonance analyses for the binding of ephrins, ligands that activate Ephrin receptors, to CS-E polysaccharides and other glycosaminoglycans.
- Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin Bl, Ephrin B2, and Ephrin B3 are examined for interactions with Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 ⁇ M. Results demonstrate variance among Ephrin species for specific binding to CS-E-enriched polysaccharides.
- Figure 17 illustrates data from EphA4 knockout mouse assays. The results demonstrate that under the conditions tested, CGN neurons from EphA4-deficient mice show reduced inhibition of neurite outgrowth by CS-E as compared to control mice.
- Figure 18 illustrates data from competition binding assays. Results demonstrate that CS-E antibody can compete for binding of Nogo Receptor (NgR) to CS-E polysaccharides on carbohydrate arrays. In addition, it is also shown that CS-E antibody blocks the inhibitory effects of CS-E polysaccharides on rat cerebellar granule neurons.
- the CS-E antibody blocks binding of NgR-Fc to CS-E on the array.
- the binding reagents mixed are: NgR alone (20OnM, left), NgR and CSE- Ab (20OnM and 10 ⁇ M, respectively, middle) or CS-E Ab alone (10 ⁇ M, right).
- Figure 19 illustrates immunostaining of lesioned rat cortex and spinal cord with the anti-CS-E antibody. Specifically, sections from rat brains with cortical lesions at 1 day, 3 days, and 7 days post lesion were
- the term "effective amount” or “therapeutically effective amount” refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below.
- the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g. axon growth.
- the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, or the physical delivery system in which it is carried.
- a "therapeutic effect,” as used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- Subject refers to an animal, such as a mammal, for example a human.
- the methods described herein can be useful in both human therapaeutics and veterinary applications.
- the patient is a mammal, and in some embodiments, the patient is human.
- chondroitin sulfate refers to a molecule comprised of one or more repeating units of one or more of the chondroitin sulfate structures provided in Figure 1.
- the term “chondroitin sulfate A” or “CS-A” refers to a molecule comprised of one or more repeating units of the CS-A structure provided in Figure 1.
- the term “chondroitin sulfate C” or “CS-C” refers to a molecule comprised of one or more repeating units of the CS-C structure provided in Figure 1.
- chondroitin sulfate E or “CS-E” refers to a molecule comprised of one or more repeating units of the CS-E structure provided in Figure 1.
- the present invention provides methods for promoting neuronal regeneration in a subject.
- the method includes the step of administering to said subject a pharmaceutical composition as provided herein comprising one or more compositions of the present invention that inhibit chondroitin sulfate (CS) mediated signaling, such as signaling via CS-A, CS-C, CS-E, or a combination thereof.
- a pharmaceutical composition as provided herein comprising one or more compositions of the present invention that inhibit chondroitin sulfate (CS) mediated signaling, such as signaling via CS-A, CS-C, CS-E, or a combination thereof.
- An exemplary composition administered to a subject includes but is not limited to a composition comprising one or more binding agents that selectively bind CS-A, CS-C, CS-E, or a combination thereof.
- compositions that are capable of inhibiting CS mediated signaling include but are not limited to NgR, Nogo, Ephrin receptor B3, p75 NTR , OMgp or a soluble fragment thereof, or a fusion or chimeric protein comprising a soluble fragment thereof.
- antagonists or inhibitors of downstream mediators of CS mediated signaling including inhibitors of MEK, epidermal growth factor receptor (EGFR), protein kinase C (PKC), RhoA, or other signaling molecules in the same or related pathways.
- potential target sites are also compared to the appropriate genome database, such that target sequences may have fewer than 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or even 1% homology to other genes.
- the readily available public database on the NCBI server, www.ncbi.nlm.nih.gov/BLAST is an example of a tool used to determine sequence homology.
- a public siRNA design tool is also readily available from the Whitehead Institute of Biomedical Research at MIT,
- CS mediated signaling such as CS-A mediated signaling, CS-C mediated signaling, or CS-E mediated signaling may be assayed by any methods known in the art as well as any methods provided herein.
- Non-limiting exemplary methods include assays for neuronal regeneration such as histochemical staining for neuronal specific markers as provided herein and further described in U.S. Patent Application Publication Nos. US20060177413 and US20070162989.
- Illustrative histochemical staining assays further include histochemical staining for neuronal specific markers, such as NgR, ⁇ lll tubulin, activin A, activin receptor Ia, activin receptor Ha, activin receptor Ib, activin receptor lib, axin 1, chondroitin sulfate 4, chondroitin sulfate E, 2',3 '-Cyclic Nucleotide 3 '-Phosphodiesterase (CNPase), Calbindin-D, Caspr2, Jagged 1, MAP2, Microtubule-Associated Proteins (MAPs), Myelin Basic Protein (MBP), NOTCHl, NOTCH2, NOTCH3, Nestin, Netrin-Gla, NeuroDl, NeuroD2, Neurofilament 200, Neurogenin 2, Neuronal Specific Enolase, Noggin, Receptor for Advanced Glycation Endproducts (RAGE), Reelin, Synaptophysin (SYP), Semaphorin 3A
- CS binding assays may be performed on intact cells expressing one or more of p75 NTR , NgR, Ephrin receptor Al, Ephrin receptor A2, Ephrin receptor A3, Ephrin receptor A4, Ephrin receptor A5, Ephrin receptor A6, Ephrin receptor A7, Ephrin receptor A8 or Ephrin receptor B3.
- these binding assays may be performed on purified protein or in cell or cell membrane extracts. These binding assays may further be performed in the presence of suspected modulators, antagonists, enhancers or agonists of the CS:receptor interaction.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arg
- sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the binding agent of the present invention, which matrices are in the form of shaped articles, e.g., films, or
- sustained-release matrices include polyesters, hydrogels (for example, poly(2- hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat No. 3,773,919), copolymers of L- glutamic acid and ⁇ -ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron DepotTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
- polyesters for example, poly(2- hydroxyethyl-methacrylate), or poly(vinylalcohol)
- polylactides U.S. Pat No. 3,773,919
- copolymers of L- glutamic acid and ⁇ -ethyl-L-glutamate non-de
- compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc.
- concentration of the antibody or fragment thereof of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight, and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected.
- compositions of the invention can be administered for prophylactic and/or therapeutic treatments.
- compositions are administered to a patient already suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications.
- compositions containing the present binding agents or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.
- compositions of the invention can be carried out with dose levels and patterns being selected by the treating physician.
- pharmaceutical composition of the invention should provide a quantity of the binding agents (or fragments thereof) of the invention sufficient to effectively treat the patient.
- the pharmaceutical composition comprising an inhibitor of CS mediated signaling such as a binding agent of the present invention may be formulated, dosed, and administered in a fashion consistent with good medical practice.
- Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the "therapeutically effective amount" of the binding agent to be administered may be governed by such considerations, and is the minimum amount necessary to promote neural growth either in vivo or in vitro.
- the binding agent need not be, but may optionally be formulated with one or more agents currently used to prevent or treat the disorder in question.
- Subjects in need thereof may present, suffer from, be suspected of suffering from, or be susceptible to any one of a number of possible neural injuries or neurodegenerative diseases such as any of the injuries, diseases or conditions provided herein including but not limited to optic nerve injury, spinal cord injury, motor nerve injury, cholinergic neuron injury, blunt trauma, severing of a nerve, nerve fiber, or nerve tissue, or injuries due to environmentally, biologically (e.g. viral infection), physically, or chemically (e.g. nerve agent, or neurotoxin) induced trauma.
- optic nerve injury e.g. viral infection
- nerve agent e.g. nerve agent, or neurotoxin
- Subjects in need thereof may present, suffer from, be suspected of suffering from, or be susceptible to any one of a number of possible neural injuries or neurodegenerative diseases such as any of the injuries, diseases or conditions provided herein including but not limited to Adrenoleukodystrophy (ALD), Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sj ⁇ gren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cerebral palsy, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial Fatal Insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (S
- the methods of the present invention further provide for contacting one or more of the pharmaceutical compositions of the present invention with one or more of extracellular matrix components or neuronal cells.
- Extracellular matrix components that may be contacted with a pharmaceutical composition of the present invention according to the methods of the present invention include but are not limited to proteoglycans such as CSPGs (e.g. CS-A, CS-C, CS-E), heparan sulfate, and keratan sulfate; non-proteoglycan polysaccharides such as hyaluronic acid; protein fibers such as collagen and elastin; cell surface proteins such as fibronectin and laminin; and enzymes such as urokinase plasminogen activator and matrix metalloproteinases.
- proteoglycans such as CSPGs (e.g. CS-A, CS-C, CS-E), heparan sulfate, and keratan sulfate
- non-proteoglycan polysaccharides such as hyaluronic acid
- protein fibers such as collagen and elastin
- Neuronal cells that may be contacted with a pharmaceutical composition of the present invention according to the methods of the present invention include but are not limited to dopaminergic neurons, cortical neurons, cholinergic neurons, GABAergic neurons, glutamatergic neurons, dopaminergic neurons, serotonergic neurons, peripheral neurons, autonomic neurons, motor neurons, sensory neurons, spinal cord neurons, interneurons, unipolar neurons, bipolar neurons, multipolar neurons, Basket cells, Betz cells, Medium spiny neurons, Purkinje cells, Pyramidal cells, Renshaw cells, Granule cells, and anterior horn cells.
- the present invention provides a method of producing a CS binding agent such as an agent that selectively binds one or more of CS-A, CS-C, or CS-E such as anti-CS-A, anti-CS-C, or anti-CS-E antibody, comprising culturing a host cell containing an isolated polynucleotide encoding an antibody of the present invention under conditions suitable for expression of the subject antibody.
- a CS binding agent such as an agent that selectively binds one or more of CS-A, CS-C, or CS-E such as anti-CS-A, anti-CS-C, or anti-CS-E antibody
- the present invention encompasses a culture medium comprising a host cell disclosed herein.
- the present invention further includes a culture fermentor comprising a plurality of host cells of the invention in a culture medium.
- Fermentation is a standard process well known in the relevant art for the breakdown and re-assembly of biochemicals and biological molecules including proteins for industry, often in aerobic growth conditions.
- a fermentor or a bioreactor as used herein refers to an apparatus that maintains optimal conditions for the growth of microorganisms, e.g. host cells of the present invention, used in large-scale or small-scale fermentation and in the commercial production of biological macromolecules including but not limited to proteins, for example, antibodies, NgR, p75 NTR , Ephrin B3 receptor, Nogo, OMgp, or fragments thereof. Fermentation chambers may be used to produce these antibodies on a large scale.
- the binding agent of the present invention can be produced in a culture fermentor.
- the present invention provides one or more compositions for promoting neuronal growth or regeneration in a subject.
- the compositions promote neuronal growth or regeneration by inhibiting CS- mediated signaling.
- these compositions may comprise binding agents that selectively bind to CS proteoglycans or to CS proteoglycan receptors, or compositions that selectively inhibit signaling events downstream of CS proteoglycan binding to cell surface or extracellular proteins.
- the present invention provides binding agents that selectively bind to one or more of CS-A, CS-C, or CS-E.
- binding agents that selectively bind to one or more of CS-A, CS-C, or CS-E reduce or eliminate the inhibitory effect of said CS proteoglycans on neuronal growth or regeneration.
- the binding agents may sequester these proteoglycans from binding to an endogenous receptor, thereby preventing the generation of an inhibitory signal in a neuron.
- the binding agents that selectively bind to CS-E may reduce or eliminate the inhibitory effect of said CS proteoglycans on neuronal growth or regeneration.
- Selective binding agents are agents that bind to a substrate, receptor or antigen with an affinity, or avidity for that substrate, receptor or antigen that is greater than for another substrate, receptor, or antigen.
- a binding agent that selectively binds CS exhibit an affinity, or avidity to CS that is greater than the affinity, or avidity of that agent for a glycan that is not CS such as for example heparan sulfate or for a molecule that is not a proteglycan such as a protein or peptide.
- a binding agent of the present invention selectively bind one or more of CS-A, CS-C, or CS-E.
- binding agents that selectively bind one or more of CS- A, CS-C, or CS-E may exhibit a greater affinity or avidity for one or more of CS-A, CS-C, or CS-E than that agent exhibits for other CS molecules, or than that agent exhibits for non-CS molecules or a combination thereof.
- a binding agent of the present invention may selectively bind CS-A and exhibit reduced or undetectable binding to CS-C or CS-E or a combination thereof.
- a binding agent of the present invention may selectively bind CS-C and exhibit reduced or undetectable binding to CS-A or CS-E or a combination thereof.
- a binding agent of the present invention may selectively bind CS-E and exhibit reduced or undetectable binding to CS-A or CS-C or a combination thereof.
- a binding agent of the present invention may selectively bind CS-E (for example) and exhibit reduced or undetectable binding to other, non CS, molecules.
- selective binding to one or more of CS-A, CS-C, or CS-E may be assayed by the use of a carbohydrate array as provided herein.
- Other selective binding agents of the present invention include binding agents that selectively bind to CS receptors such as CS-E receptors including but not limited to NgR or P75
- selective binding agents are provided that bind to one or more of CS-A, CS-C, or CS-E (e.g. CS-E) or a combination thereof with a high affinity.
- selective binding agents are provided that bind CS-E with an affinity (e.g. Kd) greater than about 10OnM, 75nM, 50 nM, 4OnM, 3OnM, 2OnM, 1OnM, 5nM, 4nM, 3nM, 2nM, or greater than about InM.
- affinity e.g. Kd
- an affinity (e.g. Kd) of 1OnM may be considered greater than an affinity of 5OnM.
- IC 50 of less than 100OnM, less than 75OnM, less than 50OnM, less than 40OnM, less than 30OnM, less than 20OnM, less than 15OnM, less than 10OnM, less than 5OnM, less than 4OnM, less than 3OnM, less than 2OnM, or less than 10, 5, 4, 3, 2, or 1 nM.
- IC 50 values can be assessed by directly measuring binding of CS-E to other targets, ligands, or receptors as provided herein, or by measuring down stream signaling events provided by CS-E as provided herein.
- Antibody binding agents of the present invention include but are not limited to full length mammalian or avian antibodies such as IgG, IgA, IgM, IgD, IgY, or IgE molecules which consist of one or more heavy chains and one or more light chains.
- the heavy and light chains are comprised of constant and variable regions.
- the variable regions contain complementarity determining regions (CDRs), which along with the surrounding framework regions provide the antigen binding regions of the antibodies.
- Antibodies may further include full length camel or shark antibodies which contain a heavy chain, but lack a light chain.
- Antibodies of the present invention may be polyclonal or monoclonal. In some cases, antibodies may be a mixture of two or more different monoclonal antibodies.
- the antibodies of the present invention may be monoclonal which refers to an antibody from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical and/or bind the same epitope(s), except for possible variants that may arise during production of the monoclonal antibody, such variants generally being present in minor amounts.
- Such monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target (e.g., CS-E), wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences.
- the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones or recombinant DNA clones.
- the selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this disclosure.
- an antibody comprising the altered target binding sequence is also a monoclonal antibody of this disclosure.
- polyclonal antibody preparations which typically include different antibodies directed against different determinants (e.g., epitopes)
- each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
- the monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.
- Monoclonal antibodies herein include chimeric antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al, Proc. Natl. Acad. ScL USA, 81:6851-6855 (1984)).
- Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc) and human constant region sequences.
- nucleic acid sequence is used interchangeably with polynucleotide, nucleotide, nucleotide sequence, nucleic acid and oligonucleotide. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown.
- modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
- the sequence of nucleotides may be interrupted by non-nucleotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
- An expression vector may be suitable for use in particular types of host cells and not others.
- One of ordinary skill in the art can readily determine through routine experimentation whether a particular expression vector is suited for a given host cell.
- the expression vector can be introduced into the host organism, which is then monitored for viability and expression of any genes contained in the vector.
- nucleic acids can be prepared from the resultant host cells, and the specific sequences of interest can be amplified by PCR using primers specific for the sequences of interest. The amplified product is subjected to agarose gel
- myeloma cells are used that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
- the myeloma cell lines are murine myeloma lines, (including, but not limited to, MOPC-21, MPC-11, SP-2 or X63-Ag8-653 cells), human myeloma cell lines (including, but not limited to, Karpas 707H, RPMI 8226, 8226 AR/NIP4-1, KM-2R, or U-266), or rat myeloma cell lines (including, but not limited to, YB2/3.O.Ag.2O, YB2/0, Y3- Agl.2.3, IR983F).
- the monoclonal antibodies secreted by the subclones can then be suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- the hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, Sequences of Proteins of Immunological Interest, 5' Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
- the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).
- a human chimeric antibody is an antibody which comprises an antibody heavy chain variable region (hereinafter referred to as "HV” or “VH”, the heavy chain being “H chain”) and an antibody light chain variable region (hereinafter referred to as "LV” or “VL”, the light chain being “L chain”), both of an animal other than human, a human antibody heavy chain constant region (hereinafter also referred to as "CH”) and a human antibody light chain constant region (hereinafter also referred to as "CL”).
- HV antibody heavy chain variable region
- LV antibody light chain variable region
- CL human antibody light chain constant region
- any animal such as mouse, rat, hamster, rabbit or the like can be used, so long as a hybridoma can be prepared there from.
- any CH can be used, so long as it is in the human immunoglobulin (hereinafter referred to as "hlg") class.
- the CH belongs to the hlgG class or one of the subclasses belonging to the HgG class, such as hlgGl, hIgG2, hIgG3 and hIgG4.
- any CL can be used, so long as it belongs to the hlg class.
- the light chain constant region (CL) of human chimeric antibody belongs to the keppa class or lambda class.
- a human CDR-grafted antibody can be produced by constructing cDNA's encoding variable regions in which CDR' s of VH and VL of an antibody derived from an animal other than human are grafted into CDR' s of VH and VL of a human antibody, inserting them into an expression vector for host cell having genes encoding human antibody CH and human antibody CL to thereby construct a human CDR-grafted antibody expression vector, and then introducing the expression vector into a modified host cell of the present disclosure to express the human CDR-grafted antibody.
- the antibody of the present invention essentially retains the ability to bind antigen compared to the parental antibody.
- the antibody of the present invention exhibits higher binding affinity to an antigen, for example, at least 1.1, 1.2, 1.3. 1.4, 1.5, 2, 3, 4, or 5 fold higher than a parental antibody. In other embodiments, the antibody of the present invention exhibits lower binding affinity to an antigen, for example, no less than 5%, 10%, 20%, 30%, 40%, or 50% of the binding affinity of a parental antibody to the antigen.
- the binding capability of the antibody of the present invention may be determined using techniques such as fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA), for example.
- the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHl) of the heavy chain.
- Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHl domain including one or more cysteines from the antibody hinge region.
- Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol group.
- F(ab').sub.2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- the anti-CS antibody provided herein such as an anti-CS-E antibody or fragment thereof is an inhibitory antibody.
- Inhibitory antibodies may inhibit one or more biological activities of the antigen to which the antibody binds.
- an inhibitory antibody can downregulate signal transduction of the corresponding antigen by inhibiting the activity of the antigen or inhibit expression of the antigen.
- the antibody is a neutralizing antibody.
- a neutralizing antibody reduces or abolishes some biological activity of a soluble antigen or of a living microorganism, such as an infectious agent.
- Neutralizing antibodies may compete with the natural ligand or receptor for its antigen.
- An anti-CS antibody of the present disclosure such as an anti-CS antibody that selectively binds to one or more of CS-A, CS-C, or CS-E can be produced by a host cell.
- a host cell includes an individual cell, cell culture, or cell line.
- Host cells include progeny of a single host cell.
- a host cell can be transfected with a heterologous sequence of the present disclosure.
- Host cells may be prokaryotic or eukaryotic, such as bacterial cells, fungal cells, animal cells, insect cells, plant cells and the like. Host cells are preferably capable of glycosylation.
- Schizosaccharomyces Kluyveromyces, Trichosporon, Schwanniomyces, Pichia, Candida and the like, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans,
- eukaryotic cells include animal cells such as mammalian cells.
- host cells preferably include, but are not limited to, Chinese hamster ovary cells (CHO) or monkey cells, such as COS cells.
- the CHO cells may include, but not be limited to, CHO/dhfr " or CHO/DG44 cells.
- the Chinese hamster ovary tissue-derived CHO cell includes any cell which is a cell line established from an ovary tissue of Chinese hamster (Cricetulus griseus). Examples include CHO cells described in documents such as Journal of Experimental Medicine, 108, 945 (1958); Proc. Natl. Acad.
- CHO-Kl ATCC CCL-61
- DUXBI l ATCC CCL-9096
- Pro-5 ATCC CCL-1781 registered in ATCC (The American Type Culture Collection)
- a commercially available CHO-S Life Technologies, Cat # 11619
- sub-cell lines obtained by adapting the cell lines using various media can also be exemplified.
- the parent cell line is derived from a lymphocytic lineage cell line, such as a B cell line.
- the host cell may be from cell lines used in hybridoma production. They can be myeloma cells, such as from murine myeloma lines, such as, but not limited to, MOPC-21, MPC-11, NSO, SP-2, Sp2/0, S 194, and X63-Ag8-653 cells; human myeloma cell lines , such as, but not limited to, Namalwa, Karpas 707H, RPMI 8226, 8226 AR/NIP4-1, KM-2R, and U-266; or rat myeloma cell lines, such as, but not limited to, YB2/0, YB2/3.O.Ag.2O, Y3- Agl.2.3, IR983F.
- myeloma cells such as from murine myeloma lines, such as, but not limited to, MOPC
- Plant host cells include plant cells of tobacco, potato, tomato, carrot, soybean, rape, alfalfa, rice, wheat, barley and the like.
- the host cell may be derived from a suitable tissue including but not limited to blood, muscle, nerve, brain, heart, lung, liver, pancreas, spleen, thymus, esophagus, stomach, intestine, kidney, testis, ovary, hair, skin, bone, breast, uterus, bladder, spinal cord, or various kinds of body fluids.
- the host cells producing the subject antibodies may be derived from any developmental stage including embryo and adult stages, as well as developmental origin such as ecotodermal, mesodermal, and ectodermal origin.
- the host cells are CHO, NSO, SP2/0, HEK293, PER.C6 or YB2/0 cells.
- Neurite outgrowth assays using dorsal root ganglions are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth.
- Acid-treated, 15-mm round German glass coverslips (Carolina Biologicals) are coated with poly-DL-ornithine (P- Orn; Sigma-Aldrich) in pH 6.5-8.5 borate buffer (approximately 0.5 mg/ml) for about 2 hr at about 37 0 C and approximately 5% CO 2 .
- the coverslips are then washed with sterile water and dried in air.
- CSPGs (approximately 1 ⁇ g/ml; Chemicon), CSPGs treated with chondroitinase ABC (Seikagaku; 1-40 mU ChABC per ⁇ g CSPG incubated for about 2 hr at approximatley 37 0 C; complete cleavage verified by SDS-PAGE), polysaccharides enriched in the CS-A, CS-C or CS-E sulfation motifs (approximately 1 ⁇ g/ml based on glucuronic acid content; Seikagaku super special grade, purified from sturgeon notochord, shark cartilage and squid cartilage, respectively), or synthetic gly copolymers (approximately 1 ⁇ g/ml) are added to the coated coverslips for about 2 hr at 37 0 C and 5% CO 2 .
- chondroitinase ABC Seikagaku; 1-40 mU ChABC per ⁇ g
- DRGs are dissected from day 4-10 chick embryos, incubated in 0.0125%-0.25% trypsin w/ EDTA for about 15 min at 37 C, triturated to dissociate to single cell suspensions, and grown on the coverslips coated with the above- mentioned substrata.
- Cells are grown in a growth medium composed of DMEM/F12, 10% horse serum, approximately 50 ng/ml NGF (Sigma-Aldrich), and Insulin-Transferrin-Selenium-X Supplement (Invitrogen) for about 12 hr.
- Growth cone collapse assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth.
- 8-Well Lab-Tek® II CC2TM Slides (Electron Microscopy Sciences) are coated with P-Orn in pH 6.5-8.5 borate buffer for about 2 hr at 37 0 C and 5% CO 2 , then coated with laminin (approximately 10 ⁇ g/ml; Invitrogen) for about 2 hr at 37 0 C and 5% CO 2 .
- DRG explants are dissected from E6-10 chick embryos and grown on the P-Orn/laminin substratum for about 24 hr, treated with the indicated polysaccharides (at approximately 10 ⁇ g/ml) or glycopolymers (at approximately 10 ⁇ g/ml) for about 30 min, fixed in PFA with 5-15% sucrose, stained using rhodamine phalloidin (Pierce), and imaged using a Nikon TE2000-S fluorescent microscope.
- the percentage of collapsed growth cones is expressed as the percentage ratio of the number of collapsed growth cones over the number of total growth cones (including collapsed and uncollapsed).
- Boundary crossing assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth.
- CS polysaccharides at various concentrations mixed with Texas Red (at approximately 0.5 mg/ml; Invitrogen) are spotted at the center of P-Orn-coated coverslips (about 5 ⁇ l) for about 2 hr at 37 0 C and 5% CO 2 .
- Cerebella are dissected from P5-9 Sprague Dawley rats, incubated in 0.0125%-0.25% trypsin w/ EDTA for about 15 min at 37 0 C, triturated to dissociate to single cell suspensions, purified on a discontinuous Percoll gradient, and cultured on the coated coverslips for about 48 hr.
- Cells are fixed in PFA with 5-15% sucrose, immunostained using an anti- ⁇ tubulin III antibody, imaged using a Nikon TE2000-S fluorescent microscope and Metamorph software, and quantified using the NIH software Image J. Axons growing toward the boundary and within 10 ⁇ m distance of the boundary are evaluated.
- Example 4 Cerebellar granule neuron (CGN) neurite outgrowth assay
- CGN neurite outgrowth assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth.
- Nitric acid-treated, 15-mm round German glass coverslips are coated with P-Orn in pH 6-8.5 borate buffer (at approximately 50 ⁇ g/ml) for about 1 hr at 37 0 C and 5% CO 2 .
- CSPGs at approximately 1 ⁇ g/ml or polysaccharides enriched in the CS-A, CS- C, or CS-E sulfation motifs (at approximately 1 ⁇ g/ml) are coated on the P-Orn-coated coverslips overnight at 37 0 C and 5% CO 2 .
- Cerebella from P5-9 Sprague Dawley rats are dissected, purified as described above, and cultured on the coated coverslips at a cell density of about 200 cells/mm 2 .
- Neurons are grown in DMEM/F12, 1% FBS, and Nl supplement for about 24 hr.
- inhibitors against MEK (PD98059, 25 ⁇ M; Calbiochem), EGFR (AG1478, 15 nM; Calbiochem), ROCK (Y27632, 5 ⁇ M; Calbiochem) and JNK (JNK Inhibitor II, 10 ⁇ M; Calbiochem) are added in solution at the start of culturing, and neurons are grown for 24 hr.
- For neurite outgrowth experiments from p75 knockout mice cerebella from P5-7 mice, either C57BL/6 wild-type or p75-/- knockout mice, are dissected and purified as described above. Neurons are plated at a density of 200-300 cells/mm and cultured for about 24 hr.
- EphA4 Eph receptor A4
- Results show that CGN neurons from EphA4-deficient mice exhibit reduced inhibition of neurite outgrowth by CS-E as compared to control mice ( Figure 17). Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth.
- CS-E antibody blocks the inhibitory effects of CS-E polysaccharides on rat cerebellar granule neurons (Figure 18B).
- P7 rat CGNs are grown for 24 hours on CS-E (1 ⁇ g/ml) in the presence of the CS-E antibody (CS-E Ab; 10 ⁇ g/ml).
- the CS-E antibody completely blocks the inhibition of neurite outgrowth caused by CS-E and CSPGs. Digestion of CS-E polysaccharides with
- chondroitinaseABC results in a small extent of residual inhibition, which is completely blocked by the CS- E antibody.
- Carbohydrate microarray assays are useful for screening for or identifying binding agents that selectively bind one or more carbohydrates including but not limited to polysaccharides such as proteoglycans including CSPGs such as CS-A, CS-C, or CS-E.
- polysaccharides such as proteoglycans including CSPGs such as CS-A, CS-C, or CS-E.
- Carbohydrate microarrays are generated by spotting approximately 1 nL of heparin (Sigma), hyaluronic acid (Sigma), dermatan sulfate (Sigma), heparan sulfate (Neoparin), chondroitin (Seikagaku), chondroitin sulfate (Seikagaku), or keratan sulfate (Seikagaku) polysaccharide solutions onto poly-L- lysine-coated slides using a Microgrid II arrayer (Biorobotics; Cambridge, UK) at room temperature and 50% humidity.
- the concentrations of the solutions range from 250 nM to 40 ⁇ M, and are calibrated to one another using the carbazole assay for uronic acid residue.
- a given concentration of each polysaccharide is spotted five to ten times at different positions on the array.
- a boundary is created around the polysaccharide spots on the slides using a hydrophobic slide marker (Super Pap Pen, Research Products International) and the slides are blocked with 5-10% fetal bovine serum (FBS) in PBS with gentle rocking at 37 0 C for about 1 hr, followed by a brief rinse with PBS.
- FBS fetal bovine serum
- Human NgR-Fc or mouse EphB2-Fc (R & D Systems) is reconstituted in 1% BSA in PBS, added to the bound region on the slides in 100 ⁇ l quantities at a concentration of 1-2 ⁇ M, and incubated at room temperature for about 3 hr.
- the slides are briefly rinsed three times with PBS, and then incubated with a goat anti-human IgG antibody conjugated to Cy3 (1:5000 in PBS) for 1 hr in the dark with gentle rocking. After rinsing two times with PBS and once with H 2 O, the microarray is analyzed at 532 nm using a GenePix 5000a scanner, and fluorescence quantification is performed using GenePix 6.0.
- Binding of the anti-CS-E antibody is evaluated using 100 ⁇ l of a 1 ⁇ g/ml ( ⁇ 7 nM) solution of antibody and a goat anti-mouse IgG secondary antibody conjugated to Cy3 (1:5000 in PBS). Under the conditions described herein, the results show that the compositions of the present invention are selective binders of one or more of CS-A, CS-C, or CS-E.
- Ephrin receptor family proteins were screened for binding to CS-E-enriched polysaccharides.
- the binding of proteins EphAl, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7 and EphA8 were examined relative to binding to Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 ⁇ M ( Figure 15).
- Ephrin family proteins a large family of protein ligands that activate Eph receptors, were screened for binding to CS-E-enriched polysaccharides.
- the binding of proteins EfnAl, EfnA2, EfnA3, EfnA4, EfnA5, EfnBl, EfnB2, and EfnB3 were examined relative to binding to Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 ⁇ M ( Figure 16). Results from this example demonstrate that EfnA3 and EfnBl selectively bind to CS-E-enriched polysaccharides.
- Oligosaccharide microarray assays are useful for screening for or identifying binding agents that selectively bind one or more carbohydrates including but not limited to polysaccharides such as proteoglycans including CSPGs such as CS-A, CS-C, or CS-E. Immobilization of oligosaccharides may be performed by conjugation of oligosaccharides to l,2-(bisaminooxy)ethane.
- Ozonolysis of the anomeric allyl group and linkage of CS compounds 1-41,2 to l,2-(bisaminooxy)ethane3 proceeds as follows: oligosaccharide (0.51 ⁇ mol) is dissolved in MeOH (500 ⁇ L) and cooled to -78 0 C. O 3 is bubbled through the reaction until a blue color persists (1 min). The reaction is then purged with N 2 until colorless, quenched with Ph 3 P beads (3 mg), and gradually warmed to rt over 12 h. The reaction is filtered and the product concentrated to afford the desired aldehyde as a white solid.
- the relative concentrations of the aminooxy oligosaccharides are calibrated to one another using the carbazole assay for uronic acid residues. Briefly, the acid borate reagent (1.5 mL of 0.80 g sodium tetraborate, 16.6 mL H2O, and 83.3 mL H2SO4) is added to 20-mL glass vials with Teflon caps.
- the aminooxy oligosaccharides are calibrated to one another using the carbazole assay for uronic acid residues. Briefly, the acid borate reagent (1.5 mL of 0.80 g sodium tetraborate, 16.6 mL H2O, and 83.3 mL H2SO4) is added to 20-mL glass vials with Teflon caps.
- oligosaccharides 50 ⁇ L of a 0.2 mg/mL stock in H2O
- carbazole reagent 50 ⁇ L of 0.1% w/v carbazole in 100% EtOH
- the solution is boiled for 15 min.
- the absorbance is read at 530 nm and compared to a D-glucuronolactone standard in H2O.
- the slides are then blocked by treatment with NaBH4 (125 mg) in 140 mM NaCl, 2.7 mM KCl, 5.4 mM Na 2 HPO 4 , and 1.8 mM KH 2 PO 4 (phosphate buffered saline, PBS, 50 mL) at rt for 5 min with gentle rocking and washed five times for 3 min with PBS.
- NaBH4 125 mg
- PBS phosphate buffered saline
- the slides are then washed as previously described and incubated with the appropriate primary antibody [anti-TNF- ⁇ (Peprotech) or anti-FGF-1 (R&D Systems); 1:1000 in 0.1% Triton X-IOO in PBS] for 2 h at rt with gentle rocking. Following the incubation, the slides are washed as previously described and treated in the dark at rt with a secondary IgG antibody conjugated to Cy3 (Amersham; 1:5000 in 0.1% Triton X-100 in PBS) at rt for 1 h with gentle rocking. The slides are washed three times for 2 min with PBS, two times for 1 min with H2O, and dried under a gentle stream of N 2 .
- Microarrays are analyzed at 532 nm using a GenePix 5000a scanner, and fluorescence quantification is performed using GenePix 6.0 software after correction for local background. Each binding agent is analyzed in triplicate, and an average fluorescence intensity of at least five spots for a given carbohydrate concentration is observed. All solutions used for the carbohydrate microarrays are sterile-filtered through a 0.2 ⁇ m syringe filter prior to use. Under the conditions described herein, the results show that the compositions of the present invention are selective binders of one or more of CS-A, CS-C, or CS-E.
- ELISA assays can be used for detecting protein binding to a receptor or substrate, detecting the presence of a protein or carbohydrate, quantifying protein expression, or quantifying protein activity. ELISA assays can also be used for identifying agents that disrupt the binding between CS and a known binding partner. Antigens are absorbed on Nunc Maxisorp 384-well plates. For CSPG binding assays, CSPGs (at approximately 10 ⁇ g/ml; in about 25 ⁇ l) are incubated in each well for about 2 hr.
- streptavidin at approximately 20 ⁇ g/ml; in about 50 ⁇ l
- biotinylated CS at approximately 20 ⁇ g/ml; in about 50 ⁇ l
- Pull down assays can be useful for identifying proteins which bind to CS (e.g. CS-A, CS-C, or
- CS-E Pull down assays can also be used for identifying agents that disrupt the binding between CS and a known binding partner.
- Full-length human p75 cDNA (amino acids 1-427; Open Biosystems) is ligated into a pcDNA3 vector (Invitrogen), modified to fuse an HA tag to the 5' end of the insert.
- Human NgR (amino acids 27-473; imaGenes) is ligated into a modified pAPtag-5 vector (GenHunter) which fuses a secretion signal sequence and a c- myc tag to the 3 ' end of the insert.
- COS-7 cells are transfected with either NgR-myc, p75-HA, or both using the Lipofectamine (Invitrogen) method.
- Cells are lysed about 2 days after transfection with 0.5-2% Triton X-100 in PBS containing a protease inhibitor mixture (Roche) by rocking for 15-90 min at 4 0 C.
- the lysates are clarified by centrifugation at 5-25,000 rpm for 1-30 min.
- Biotin is attached to the free amino group of the residual core peptides of CS-C and CS-E polysaccharides (Seikagaku). Briefly, CS-C and CS-E (about 2 mg each) are dissolved in about 1 mL of 0.015-0.1 M NaHCO 3 for about 30 min at room temperature. EZ-Link Sulfo-NHS-LC-LC-Biotin (approximately 0.25 mg; Pierce) is dissolved in about 1 mL OfH 2 O and added to each CS sample. The solution is mixed at room temperature for about 1-10 hr, lyophilized, resuspended in H 2 O, and subjected to gel filtration using Sephadex G-50 or G-25 (Amersham) to remove excess biotin.
- EZ-Link Sulfo-NHS-LC-LC-Biotin (approximately 0.25 mg; Pierce) is dissolved in about 1 mL OfH 2 O and added to each CS sample. The solution
- Biotinylated CS-C or CS-E (approximately 280 ⁇ g each) in 100-500 ⁇ l of PBS is added to streptavidin agarose resin (about 140 ⁇ l; Pierce) and incubated at room temperature for about 1 hr. The supernatant is removed, and the resin washed 1-5 times with about 500 ⁇ l of PBS to remove unconjugated CS. Clarified COS-7 cell lysates are diluted 1:5 to 1:20 with PBS, and further diluted approximately 1:2 with H 2 O.
- Diluted lysate (about 500 ⁇ l, corresponding to approximately 0.8 mg/ml total protein) is precleared by incubation with unconjugated streptavidin agarose resin (e.g. 30 ⁇ l) with mixing for about 1 hr at 4 0 C.
- the supernatant is collected, added to either CS-C or CS-E streptavidin agarose resin (e.g. 30 ⁇ l), and incubated with mixing for about 4 hr at 4 0 C.
- the supernatant is removed, and the resin is washed 1-5 times with about 500 ⁇ l PBS.
- Resin is boiled with about 30 ⁇ l of 2X loading dye (100 mM Tris, 200 mM DTT, 4% SDS, 0.10% bromophenol blue, 20% glycerol), and the eluates are collected and separated by SDS-PAGE.
- NgR-myc and p75-HA are detected by immunoblotting with myc-tag (Cell Signaling) or HA-tag (Sigma) antibodies.
- myc-tag Cell Signaling
- HA-tag Sigma
- both control and active flow cells are exposed to a 1:1 mixture of N- hydroxysuccinimide (NHS) and l-ethyl-S ⁇ -dimethylaminopropyl-carbodiimide (EDC) for 1-10 min at a flow rate of about 10 ⁇ L-mkf 1 .
- NHS N- hydroxysuccinimide
- EDC l-ethyl-S ⁇ -dimethylaminopropyl-carbodiimide
- 1-10 mM carbohydrazine is injected at the same flow rate for about 5-15 min.
- Ligand is covalently attached to the surface by injecting a 0.1-1 mM solution of synthetic CS-E tetrasaccharide bearing an aldehyde group on a reducing-end linker, onto the active flow cell briefly at a high flow rate (approximately 10 s, 60 ⁇ L-min "1 ), followed by a 20 min injection of 0.1 M sodium cyanoborohydride in 0.1 M sodium acetate pH 4.0 at about 2 ⁇ L-mkf 1 . Because of the low molecular weight of the CS-E tetrasaccharide, it may be difficult to observe the amount of ligand bound to the surface.
- Affinity analysis is measured by injecting the antibody for about 3600 s at 5 ⁇ L-mirT ⁇ After 3600 s, the surface is regenerated with a 60 s injection at about 10 ⁇ L-mirf ⁇ The data is analyzed by plotting the response at equilibrium versus concentration and fitting the resulting curve to the Langmuir equation.
- Streptavidin (at approximately 1 ⁇ M, 0.01 M NaOAc, pH 5.0) is conjugated to the activated surfaces until saturation, followed by ethanolamine blocking.
- Biotinylated CS-E composed of -61.5% of the CS-E disaccharide motif, the remainder of which is a mixture of CS- A, CS-C, and unsulfated disaccharides, is immobilized to flow cell 2 to give an R L of 25 response units (RU); biotinylated CS-C is immobilized to flow cell 4 to give a similar R L .
- Flow cells 1 and 3 are used as controls to subtract bulk response.
- NgR-Fc is passed over the surface at 25 0 C with a flow rate of about 80 ⁇ L-mkf 1 for 240 s, and the dissociation monitored for 600 s.
- the surface is regenerated by three injections of 90 s of 2.5 M MgCl 2 at 30 ⁇ L-mirT ⁇ NgR-Fc injection results in binding of NgR-Fc to CS-E polysaccharides with two apparent kinetic processes, presumably caused by variations in the density of CS-E motifs along the polysaccharide chain. No binding is detected to CS-C-enriched polysaccharides.
- the resulting sensorgrams are analyzed using Biacore TlOO evaluation software V2.0 and fit to the heterogeneous ligand model with the value of bulk refractive index (RI) set to zero. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at selectively binding to CS-E.
- the assay further shows that NgR and p75 bind to CS-E but not CS-C.
- mice are given an overdose of pentobarbital and are transcardially perfused with 4% PFA. Eyeballs still attached with the optic nerve are dissected and post-fixed in 4% PFA overnight. Following cryoprotection with 30% sucrose in PBS, tissues are embedded in O.C.T. and serial sectioned for 5-20 ⁇ m along the longitudinal direction of the nerve. For immunofluorescence labeling, the sections are washed with PBS, pre-incubated in a blocking buffer (approximately
- the number of regenerating axons is counted at 125 ⁇ m stepwise from the crush site of the optic nerve. The total number of regenerating axons is estimated.
- the total number of ⁇ lll-tubulin positive cells is counted in at least 3 retinal sections per retina. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth, nerve growth, neuron survival, and neuronal regeneration, and are also effective at inhibiting growth cone collapse.
- the optical nerve regeneration assay can be used to asses nerve growth, neurite outgrowth, growth cone collapse, neuron survival, and neuronal regeneration.
- gelfoam that has been soaked in a solution containing control IgG, anti-CS-E antibody (1.7 mg/ml), chondroitinase ABC (chABC; 50 U/ml), or chABC (50 U/ml) plus anti-CS-E (1.7 mg/ml) antibody is placed around the crush site of the nerve and replaced at day three and six after injury.
- mice that received an intravitreal injection of CPT-cAMP (100 mM, 2 ⁇ l) alone or CPT-cAMP plus anti-CS-E (1.7 mg/ml) antibody treatment placed around the crush site of the nerve are studied.
- CPT-cAMP 100 mM, 2 ⁇ l
- CPT-cAMP plus anti-CS-E 1.7 mg/ml
- To label retinal ganglion cell axons 2 ⁇ l of a solution containing an anterograde axon tracer, CTB, is injected intravitreally 3 days before mice were sacrificed. The extent of axonal regrowth is assessed 2 weeks after injury. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth, nerve growth, neuron survival, and neuronal regeneration, and are also effective at inhibiting growth cone collapse.
- mice can be used to assess the efficacy of the methods and compositions of the present invention in promoting the enhancement of locomotor function, bladder function, neuromuscular functional recover or walking in a subject.
- mice are anesthetized with an IP injection of Avertin. Hair is removed by shaving, and the skin is treated with betadine. A midline incision is made over cervical spinous processes and paravertebral muscles are separated from the vertebrae. A laminectomy is performed at T8 or C5. Dorsal hemisections are performed using a Moria micro knife. After producing the spinal cord injuries, the muscle is sutured in layers, and the skin is closed with wound clips. Post-operatively, animals receive saline, dextrose, Baytril, and Buprenorphine subcutaneously and are placed on a warming blanket at 37°C overnight. Bladders are manually expressed for the first week.
- Hindlimb motor function during locomotion is assessed at 2, 7, 14, 21, 28, 35, and 42 days post-injury using the BBB and BMS scales. Kinematic analyses are carried out at 22 and 43 days; hindlimb placement on a horizontal ladder with variably spaced rungs is be assessed at 20 and 40 days post-injury.
- Forepaw grip strength is repeatedly measure over time in mice and rats using a Grip Strength Meter distributed by SciPro, Inc.
- the task takes advantage of the natural tendency of mice to reach out and grasp nearby objects. In brief, mice are handled and trained until they became accustomed to having one paw restrained with tape. The tape prevents that foot from being used to grasp the bar so that grip strength can be measured independently for each paw. For testing, mice are held by the base of the tail close to the bar of the grip strength meter, which they grasp with the free paw. The mice are pulled gently away until they release their grip, and the device measures the maximal force exerted before the paw releases its grip. This task offers considerable advantages because maximal grip strength is remarkably consistent from animal to animal and over prolonged periods of repeated testing.
- CST corticospinal tract
- Rho activation assay can be used to assay for inhibitors of CS mediated Rho activation.
- RhoA-GTP levels are measured using methods known in the art (See e.g., Nature Neuroscience 7, 221-228 (2004); Neuron 45, 353-359 (2005); and Journal of Cell Biology 157, 565-570 (2002)). Briefly, the RhoA-binding domain of the effector protein Rhotekin can be used to affinity precipitate the GTP-bound form of RhoA. The amount of precipitated GTP -RhoA can then be determined for example by blotting or ELISA. RhoA activation levels are compared to those obtained using Nogo or OMgp alone. The results of these assays demonstrate that the methods and compositions of the present invention are effective at inhibition of CS mediated signaling.
- Observing the increased expression of a protein in response to neural injury further emphasizes its importance in the tissue response signaling chain of events.
- expression of the CS-E motif was assessed after brain injury in vivo in rats as described herein using histochemical staining methods. Sections from rat brains with cortical lesions at 1 day, 3 days, and 7 days post lesion were immunostained with the CS-E antibody. Increased immunostaining around the lesion was observed at all three time points, and levels of staining appeared highest at 3 days post-lesion. At 1 day post lesion, there was a diffuse increase in immunostaining confined to the region immediately adjacent to the lesion.
- Immunostaining was also assessed 2 days following a dorsal funiculus lesion of the rat spinal cord. As with cortical lesions, there was a general increase in immunostaining in the lesion margin, and some cells around the lesion expressed CS-E at a fairly high level. Some cells in the gray matter also stained for CS-E, but not as intensely as those near the lesion. Dorsal and ventral white matter also stained for CS-E in a pattern that resembled neurofilament expression.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
This invention provides methods and compositions for reducing chondroitin-sulfate- proteoglycan-mediated inhibition of neuronal growth. The methods and compositions provided herein are particularly useful for treatment of neuronal damage or degeneration.
Description
METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE OR DEGENERATION
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0001] This invention was made with government support under RO 1GM093627-01 awarded by the National Institutes of Health. The government has certain rights in the invention.
RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 61/271,705, filed July 24, 2009, which is incorporated by reference herein in its entirety.
BACKGROUND OF THE INVENTION
[0003] Each year more than 20 million people suffer from nerve damage or degeneration. Nerve damage or degeneration can be caused by a number of factors including various diseases, nutritional deficiencies, mechanical impact or trauma, and adverse effects of existing drugs. The common diseases that can manifest in nerve damage or degeneration are various types of motor neuron disorders, diabetic neuropathy, infectious diseases, neoplastic conditions, and autoimmune diseases. Nerve damage is most commonly observed in patients suffering from autoimmune diseases such as multiple sclerosis, Guillain Barre syndrome, myasthenia gravis, lupus, and even inflammatory bowel disease. Certain infectious diseases can also cause nerve damage or degeneration. These infectious diseases include Lyme disease, herpes virus, HIV, and hepatitis C. A wide variety of mechanical impact and trauma can cause varying degrees of nerve damages including pinched or severed nerves, spinal cord injuries, and autonomic, sensory, or motor nerve injuries. Additionally, neurodegenerative diseases including but not limited to Parkinson's (degeneration of the dopaminergic nigrastriatal pathway), Alzheimer's (degeneration of neurons in the cerebral cortex and certain subcortical regions), and Huntington's disease (degeneration of striatal neurons) can cause or contribute to nerve degeneration.
[0004] Current treatments for nerve damage or degeneration are primarily palliative and not curative. In particular, there is no effective treatment for regenerating or repairing damaged nerves. One major obstacle to axonal regeneration is the growth-inhibitory extracellular environment of the encountered axons. This inhibitory activity is principally attributable to components of CNS myelin and molecules present in the extracellular and cell-surface environment. These components include a variety of proteins, proteoglycans or polysaccharides, of which glycosaminoglycans are thought to play a key role in mediating these inhibitory signals.
[0005] Glycosaminoglycans have an inherent capacity to encode functional information that rivals DNA, RNA and proteins. Specifically, these polysaccharides display diverse patterns of sulfation that are tightly regulated in vivo Kitagawa, H. et al., J. Biol. Chem. 272, 31377-31381 (1997) and Plaas, A.H.K. et al, J. Biol. Chem. 273,
12642-12649 (1998). Chondroitin sulfate proteoglycans (CSPGs) such as neurocan, phosphacan, NG2 and brevican are upregulated following CNS injuries and have been implicated as potent inhibitors of axonal regeneration. CSPGs are a class of glycosaminoglycans composed of chondroitin sulfate (CS) polysaccharides consisting of units of the repeating disaccharide D-glucuronic acid (GIcA) and iV-acetyl-D-galactosamine (GaINAc). The sugar hydroxyls may be variably sulfated to give rise to diverse sulfation patterns. Chemical structures of major sulfation motifs found in the mammalian nervous system include CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-E (GlcA-4S, 6SGaINAc). CSPGs are thought to interact with a variety of proteins and other signaling molecules
including but not limited to the cell surface protein p75NTR, as well as other extracellular proteins. These cell surface receptors and extracellular proteins in turn may transduce binding events into an inhibitory signal via downstream intracellular mediators of CS signaling.
SUMMARY OF THE INVENTION
[0006] The present invention addresses the need for alternative treatments for neuronal damage and other neurodegenerative diseases existing in the art.
[0007] In one embodiment, the present invention provides a method for promoting neuronal regeneration in a subject in need thereof. The method comprises administering to said subject a pharmaceutical composition comprising a physiologically acceptable carrier and an agent that inhibits chondroitin sulfate E (CS-E) mediated signaling. The agent used in the subject method is typically present in an amount effective in promoting neurite outgrowth in said subject. In one aspect of the embodiment, the pharmaceutical composition administered to said subject comprises a chondroitin sulfate E (CS-E) binding agent. In another aspect, the method comprises inhibiting CS-E mediated signaling, wherein said signaling comprises intracellular signaling mediated by one or more cellular proteins selected from signaling molecules including but not limited to mitogen activated protein kinase kinase (MEK), epidermal growth factor receptor (EGFR), protein kinase C (PKC), rho kinase (RhoK), and RhoA.
[0008] In another embodiment, the present invention provides a method of treating a subject suffering from a neural injury comprising administering to said subject in need thereof a pharmaceutical composition comprising therapeutically effective amount of a chondroitin sulfate E (CS-E) binding agent and a physiologically acceptable carrier.
[0009] In another embodiment, the present invention provides a method of reducing chondroitin proteoglycan (CSPG)-mediated inhibition of neuronal growth. The method typically comprises: contacting a biological sample comprising one or more extracellular matrix components with a chondroitin sulfate E (CS-E) binding agent under conditions sufficient to reduce CS-E mediated signaling in said neuronal cell.
[0010] In a further aspect of any one of the foregoing embodiments, the methods of the present invention provide for administering chondroitin sulfate E (CS-E) binding agents that are antibodies that selectively bind to CS-E. The antibodies may be polyclonal or monoclonal, or a fragment thereof.
[0011] In a further aspect of any one of the foregoing embodiments, the methods of the present invention provide for administering chondroitin sulfate E (CS-E) binding agents that are soluble proteins and can selectively bind CS- E. The soluble proteins are comprised of soluble domains of one or more of p75NTR, NgR, Nogo, OMgp, Ephrin receptor B3, Ephrin A3, Ephrin receptor A4, Ephrin Bl, which selectively bind to CS-E.
[0012] In a further aspect of any one of the foregoing embodiments, the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that inhibits CS-E signaling. Inhibition of CS-E signaling is evidenced by, e.g., reduction of RhoA activation by CS-E in a neuronal cell or any cell expressing p75NTR, or reduction of binding of CS-E to a surface of a neuronal cell or a cell expressing p75NTR.
[0013] In a further aspect of any one of the foregoing embodiments, the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that inhibits CS-E mediated growth cone collapse.
[0014] In a further aspect of any one of the foregoing embodiments, the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that promotes neurite outgrowth in vitro.
In a further aspect, the methods of the present invention provide for administering a chondroitin sulfate E (CS-E) binding agent that exhibits a strong binding affinity for CS-E (e.g., a Kd value less than about 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1 μM, or 1 mM) as ascertained in an in vitro binding assay. The binding assay may be a surface plasmon resonance assay, such as in Example 9.
[0015] In yet another aspect, the present invention provides for administering a chondroitin sulfate E (CS-E) binding agent that promotes or improves locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in a subject. The subject may be suffering from spinal cord injury, optical nerve injury, motor nerve injury, stroke, a neurodegenerative disease, or a combination thereof.
[0016] In yet another embodiment, the present invention provides a pharmaceutical composition comprising a chondroitin sulfate E (CS-E) binding agent and a physiologically acceptable carrier. In one aspect of this embodiment, the chondroitin sulfate E (CS-E) binding agent is an antibody exhibiting binding selectively to CS-E. In another aspect of this embodiment, the chondroitin sulfate E (CS-E) binding agent is a monoclonal antibody exhibiting binding selectively to CS-E. In another aspect, the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E. In yet another aspect, the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of NgR that selectively binds to CS-E. In a further aspect, the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of p75NTR that selectively binds to CS-E. In still another aspect, the chondroitin sulfate E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of Nogo, OMgp, or Ephrin receptor B3 (EphB3), Ephrin A3 (Efn A3), Ephrin receptor A4 (EphA4), Ephrin Bl (Efn Bl) that selectively binds to CS-E. In yet another aspect, the chondroitin sulfate E (CS-E) binding agent inhibits CS-E signaling as evidenced by inhibition of RhoA activation in a neuronal cell or a cell expressing p75NTR, or inhibition of binding of CS-E to a surface of a neuronal cell or a cell expressing p75NTR. In yet still another aspect, the chondroitin sulfate E (CS-E) binding agent promotes neurite outgrowth in vitro, or improves locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in a subject.
INCORPORATION BY REFERENCE
[0017] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0019] Figure 1: depicts CS polysaccharides composed of units of the repeating disaccharide D-glucuronic acid (GIcA) and iV-acetyl-D-galactosamine (GaINAc). The sugar hydroxyls are variably sulfated to give rise to diverse sulfation patterns. Chemical structures of major sulfation motifs found in the mammalian nervous system: CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-E (GlcA-4S, 6SGaINAc).
[0020] Figure 2: shows that the CS-E sulfation motif inhibits DRG neurite outgrowth and induces growth cone collapse. (A) Dissociated chick E 7 DRGs are cultured on a substratum of poly-DL-ornithine (P-Orn control), chicken brain-derived CSPGs, chondroitinase ABC -treated CSPGs, or CS polysaccharides enriched in the CS-A, CS-C or CS-E sulfation motifs. Representative images and a bar graph measuring average neurite length (± SEM, error bars) from three experiments (n = 50-200 cells per experiment) are shown. Scale bars, 100 μm. (B)
Polysaccharides enriched in the CS-E sulfation motif, but not the CS-A or CS-C motifs, inhibit DRG neurite outgrowth in a dose -dependent manner. (C) CS-E-enriched polysaccharides repel axon crossing in a boundary assay. Polysaccharides (1 mg/ml) or PBS control are mixed with Texas Red and spotted on P-Orn coated coverslips. Dissociated rat P5-9 CGN neurons are immunostained with an anti-βlll-tubulin antibody. Representative images and a bar graph measuring percentage of axon crossing (± SEM, error bars) from two experiments (n = 30-50 axons per experiment) are shown. Scale bars, 50 μm. (D) CS-E-enriched polysaccharides, but not CS-A- or CS-C- enriched polysaccharides, induce growth cone collapse. DRG explants from chick E7-9 embryos are grown on a P- Orn/laminin substratum, treated with medium (control) or the indicated polysaccharides, and stained with rhodamine-phalloidin. Representative images and a graph measuring percentage of growth cone collapse (± SEM, error bars) from five experiments (n = 50-100 growth cones per experiment) are shown. Arrows indicate collapsed growth cones. (E) Structures of synthetic glycopolymers displaying pure CS-A, CS-C and CS-E disaccharides. (F) The synthetic CS-E glycopolymer inhibits DRG neurite outgrowth, whereas glycopolymers containing pure CS-A or CS-C sulfation motifs have little effect. (G) The synthetic CS-E glycopolymer, but not the CS-A or CS-C glycopolymer, induces DRG growth cone collapse. All statistical analyses were performed using the one-way ANOVA (*P < 0.0001, relative to control).
[0021] Figure 3: illustrates that the CS-E sulfation motif is found on CSPGs and activates ROCK, EGFR, and MAP kinase pathways. (A) Anti-CS-E monoclonal antibody binds selectively to CS-E-enriched polysaccharides on carbohydrate microarrays. Little binding to other sulfated CS polysaccharides and glycosaminoglycan classes is detected. Microarrays are incubated with anti-CS-E antibody, followed by a Cy3 -conjugated anti-mouse IgG secondary antibody, and analyzed using a GenePix 5000a scanner. Experiments are done in triplicate (n =10 per condition). (B) Dose -dependent binding of the anti-CS-E antibody to CSPGs, as shown in an enzyme-linked immunosorbent assay binding curve. Average values (± SD, error bars) are shown for one representative experiment. The experiment is repeated three times with similar results. (C) Both CS-E polysaccharides and CSPGs require activation of MEK, EGFR, and ROCK for inhibition of neurite outgrowth. Inhibitors against MEK (PD98059, 25 μM), EGFR (AG1478, 15 nM), and ROCK (Y27632, 5 μM) rescue CS-E- and CSPG-mediated inhibition of neurite outgrowth in dissociated rat P5-9 CGN cultures, whereas JNK inhibitor II (10 μM) has no effect. Quantification from at least three experiments is reported. Treatment with each inhibitor alone has no effect on neurite outgrowth when compared to untreated neuronal cultures (fig. S8). (One-way ANOVA, *P < 0.0001, relative to CS-E control without inhibitors, **P < 0.0001, relative to CSPG control without inhibitors; n = 50-200 cells per experiment).
[0022] Figure 4: illustrates that CS-E interacts with NgR and may require p75NTR to inhibit neurite outgrowth. (A) NgR binds selectively to CS-E-enriched polysaccharides on carbohydrate microarrays. Microarrays are incubated with NgR-Fc, followed by a Cy3 -conjugated anti-mouse IgG secondary antibody, and analyzed using a GenePix 5000a scanner. Graphs show quantification from six experiments (n = 10 per condition). (B) Pull-down of full-length, native NgR by CS-E. COS-7 cell lysates expressing full-length myc-NgRl and HA-p75NTR are incubated
with biotinylated CS-E-enriched polysaccharides bound to streptavidin beads. NgR binding is detected by immunoblotting with an anti-myc antibody. Similar results are obtained using COS-7 lysates expressing myc-NgRl alone, and no binding to HA-p75NTR is detected. The experiment is repeated in triplicate. (C) Neurite outgrowth inhibition mediated by CS-E and CSPGs is significantly attenuated in p75NTR-deficient neurons. CGN neurons from wild type or p75NTR-deficient mice are cultured on a substratum of P-Orn and CS-E or CSPGs. Neurites are visualized by staining with an anti-βlll-tubulin antibody, and the percent neurite outgrowth is quantified relative to the wild-type control. Quantification from three experiments is reported. (One-way ANOVA, *P < 0.0001, relative to wild-type P-Orn control, **P < 0.0001, relative to p75-/- P-Orn control; n = 50-200 cells per experiment).
[0023] Figure 5: illustrates that the CS-E-specific antibody blocks CSPG-mediated growth inhibition and promotes optic nerve regeneration in vivo. (A) Anti-CS-E antibody, but not anti-CS-A or IgG control antibody, reverses inhibition of neurite outgrowth mediated by CSPGs. Dissociated chick E7 DRGs are cultured on a substratum of P-Orn (control; black) or CSPGs (0.5 μg/ml; grey or blue) in the presence of the indicated antibodies (0.1 mg/ml) for 12 hr. Treatment with each antibody alone (black bars) has no effect on neurite outgrowth relative to untreated neurons cultured on P-Orn. Neurites are visualized by staining with an anti-βlll-tubulin antibody, and quantification from three experiments is shown (One-way ANOVA, *P < 0.0001, relative to CSPG without antibody treatment control; n = 50-200 cells per experiment). (B) (a, b) Induction of CS-E expression after optic nerve injury. Immunofluorescence labeling of CS-E expression in optic nerve sections at day 1 after sham-operation (a) or optic nerve crush injury (b). Note upregulation of CS-E within a 200 - 500 μm radius around the injury site (marked by an asterisk), (c to f) Anti-CS-E antibody promotes optic nerve regeneration in vivo. Representative epifluorescence photomicrographs of optic nerve sections taken from mice treated with control IgG (c), anti-CS-E antibodies (d), chondroitinase ABC (e) or chondroitinase ABC plus anti-CS-E antibody (f). Retinal ganglion cell axons (red) are labeled by an anterograde axon tracer, CTB, which is injected into the vitreous 3 days prior to sacrifice, followed by immunostaining with goat anti-CTB antibody, (g to i) High magnification images of insets in c, d, and e, respectively. Scale bars, 75 μm (a-f); 25 μm (g-i). Arrowheads indicate growth cone structures. (C) Quantification of axon regeneration in vivo. Nerve fibers are counted at 125-μm intervals from the crush site from three nonconsecutive sections, and the number of fibers at a given distance is calculated (± SEM, error bars). Both the anti-CS-E- and chABC-treated groups show significantly more regenerating axons as compared with the control IgG antibody-treated group (ANOVA with Bonferroni posttests at each distance, *P < 0.001 as compared to controls; n = 6 for each group). (D) Quantification of the distances of axon regeneration. Longest distance of axon regeneration is measured from at least 4 nonconsecutive optic nerve sections from each mouse (± SEM, error bars). Combined treatment of CS-E mAb and 8-(4-chlorophenylthio)-cyclic AMP (CPT-cAMP) more than doubles the distance of axon regeneration but does not affect the number of regenerating axons compared to the anti-CS-E or CPT-cAMP treatment alone.
[0024] Figure 6: illustrates that polysaccharides enriched in the CS-E sulfation motif (-60% CS-E content), but not CS-A or CS-C, inhibit the neurite outgrowth of cerebellar granule neurons (CGNs). (A) Dissociated P5-9 rat CGNs are cultured on a substratum of polysaccharides enriched in the CS-A, CS-C or CS-E sulfation motifs (1 μg/ml) for 24 h. Cells are immunostained using an anti-βlll-tubulin antibody, imaged and quantified using the NIH software Image J. Representative images are shown on the top, and a graph measuring the average neurite length (± SEM, error bars) from at least three experiments is shown on the bottom (One-way ANOVA, *P < 0.0001, relative to P-Orn control; n = 50-200 cells per experiment). (B) Polysaccharides enriched in the CS-E sulfation motif, but not the CS-A or CS-C motifs, inhibit CGN outgrowth in a dose-dependent manner.
[0025] Figure 7: depicts representative images of the (A) axon repellant activity of CS-A and CS-E polysaccharides at high sugar concentrations (10 mg/ml), (B) inhibition of chick E7 DRG outgrowth by the synthetic glycopolymers, and (C) growth cone collapse of chick E7-9 DRG explants induced by the synthetic gly copolymers. Arrows indicate collapsed growth cones. Scale bars, 100 μm.
[0026] Figure 8: illustrates that the anti-CS-E antibody binds selectively to a pure, synthetic CS-E tetrasaccharide and CS-E-enriched polysaccharides, whereas it does not bind to CS-A or CS-C tetrasaccharides or polysaccharides. (A) Tetrasaccharides containing pure CS-A, CS-C or CS-E motifs are conjugated to bovine serum albumin (BSA) and spotted on nitrocellulose membranes at the indicated amounts. Binding of the antibody to the membrane is detected using a goat anti-mouse secondary antibody conjugated to Alexa Fluor® 680 and imaged using an Odyssey Infrared Imaging System. The anti-CS-E antibody binds in a concentration-dependent manner to the BSA-CS-E tetrasaccharide conjugate but does not bind significantly to BSA-CS-A, BSA-CS-C, or BSA alone. (B) Binding of the anti-CS-E antibody to biotinylated CS polysaccharides enriched in the CS-A, CS-C, or CS-E sulfation motifs. Biotinylated CS polysaccharides are adsorbed on streptavidin-coated plates, and antibody binding to the plate is detected using a goat anti-mouse secondary antibody conjugated to horseradish peroxidase. Experiments are repeated in triplicate.
[0027] Figure 9: depicts the results of kinetic analysis of the interaction between the anti-CS-E antibody and CS-E tetrasaccharide by surface plasmon resonance. (A) The synthetic CS-E tetrasaccharide is covalently immobilized onto the surface via reductive amination chemistry. Binding kinetics are monitored at 25 0C by injecting the CS-E antibody over the surface for 300 s at 30 μL-min"1 and recording the dissociation for 900 s. The surface is regenerated with 6 M guanidine HCl. The resulting sensorgrams are fit to the bivalent analyte model. According to this model, a surface-bound analyte can bind another ligand molecule with the free binding site. The kinetic parameters of the fit, with standard errors in parenthesis, are tabulated in (C). (B) The affinity is also measured by injecting the antibody over the surface for 3600 s to give sufficient time to reach equilibrium. The response at equilibrium is plotted versus concentration to give a KD value of 4.3 nM.
[0028] Figure 10: illustrates that the Fc domain and the axon guidance receptor EphB2 do not bind to CS-E polysaccharides on carbohydrate microarrays. 10(A) depicts the binding of NgR-Fc to the array. 10(B) depicts the control Fc, which does not exhibit binding to the arrays. (C) EphB2-Fc does not bind to glycosaminoglycans on carbohydrate microarrays. Each bar represents an average of 10 spots from one typical array. Relative binding is plotted by comparison to the fluorescence intensity of NgR-Fc binding to 5 μM CS-E.
[0029] Figure 11: depicts the results of kinetic analysis of NgR-binding to CS-E-enriched polysaccharides by surface plasmon resonance. (A) Biotinylated CS-E polysaccharides are immobilized onto the surface via streptavidin capture (RL = 25 RU). NgR is passed over the surface at 80 μL-mkf1 at 25 0C for 240 s. After monitoring the dissociation for 600 s, the surface is regenerated by three successive injections of 2.5 M MgCl2 of 90 s at 30 μL-mkf l. The resulting sensorgrams are fit to the heterogeneous ligand model (black lines), where the bulk refractive index (RI) is set as a constant value of zero. The model predicts two independent binding sites. The kinetic parameters derived from the fitting are tabulated in (C), with the standard error in parentheses. (B) Simulation of curves representing the individual binding components of the heterogenous ligand model. A binding site with picomolar affinity (solid lines) binds approximately 6 molecules of NgR per polysaccharide, based on solving the equation Rmax = RL-(MWAZMWL)-S111 for Sm, the number of binding sites. The observed nanomolar binding site (dashed lines)
binds approximately 2 molecules of NgR per polysaccharide. (D) No binding of NgR to CS-C polysaccharides was observed (black line).
[0030] Figure 12: depicts the results of binding specificity of tested molecules to CS-E containing microarray. (A) EphB3-Fc binds to CS-E with high specificity by microarray analysis. (B) No binding to CS-E, nor any other glycosaminoglycan tested in A was detected for EphB2-Fc (data not shown). (C) Surface plasmon resonance of EphB3-Fc binding to CS-E polysaccharide. Data show binding at the following concentrations: 3072, 1536, 768, 384, 192, 96, 48, 24, 12, 6, 3 nM. (D) A comparison of EphB3-Fc and EphB2-Fc binding to CS-E by SPR. While high concentrations of EphB3 gives a strong response by SPR (black, 3 μM; red, 1.5 μM), EphB2 shows no binding to CS-E at these concentrations. (E) Tabulation of the binding rate constants of the EphB3-Fc/CS-E interaction. (F) Full-length EphB3 is pulled down by CS-E, but not CS-C, as shown on an immunoblot.
[0031] Figure 13: illustrates that under the conditions tested, an anti-CS-E antibody does not affect the survival or intrinsic growth status of retinal ganglion cells. (A) Application of anti-CS-E antibody does not change retinal ganglion cell survival after optic nerve injury. Bar graph indicates relative survival of retinal ganglion cells in control IgG or anti-CS-E antibody-treated mice that are quantified at 14 days post optic nerve injury. (B)
Comparison of axon regeneration in vivo induced by anti-CS-E and/or CPT-cAMP. Retinal ganglion cell axons are counted at 125-μm intervals from the crush site from three nonconsecutive sections, and the number of fibers at a given distance is calculated (± SEM, error bars). ANOVA with Bonferroni posttests at each distance, *P < 0.001 as compared to controls; n = 6 for each group.
[0032] Figure 14: illustrates data from an oligosaccharide microarray experiment for detection and analysis of chondroitin sulfate binding agents. The results demonstrate that under the conditions tested, Nogo-66 (top panel), the amino terminal domain of Nogo (middle panel), and oligodendrocyte myelin protein (OMgp) (bottom panel) bind to CS-E polysaccharides. Nogo and OMgp have been implicated in inhibiting neuronal growth after injury.
[0033] Figure 15: illustrates data from carbohydrate microarray and surface plasmon resonance analyses for the binding of Ephrin receptors to CS-E polysaccharides and other glycosaminoglycans. The relative binding of proteins EphAl, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7 and EphA8 are examined for interactions with Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 μM. Results demonstrate variance among Ephrin receptor species for specific binding to CS-E-enriched polysaccharides.
[0034] Figure 16: illustrates data from carbohydrate microarray and surface plasmon resonance analyses for the binding of ephrins, ligands that activate Ephrin receptors, to CS-E polysaccharides and other glycosaminoglycans. The relative binding of proteins Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin Bl, Ephrin B2, and Ephrin B3 are examined for interactions with Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 μM. Results demonstrate variance among Ephrin species for specific binding to CS-E-enriched polysaccharides.
[0035] Figure 17: illustrates data from EphA4 knockout mouse assays. The results demonstrate that under the conditions tested, CGN neurons from EphA4-deficient mice show reduced inhibition of neurite outgrowth by CS-E as compared to control mice.
[0036] Figure 18: illustrates data from competition binding assays. Results demonstrate that CS-E antibody can compete for binding of Nogo Receptor (NgR) to CS-E polysaccharides on carbohydrate arrays. In addition, it is also shown that CS-E antibody blocks the inhibitory effects of CS-E polysaccharides on rat cerebellar granule neurons.
In Figure 18A, the CS-E antibody blocks binding of NgR-Fc to CS-E on the array. The binding reagents mixed are: NgR alone (20OnM, left), NgR and CSE- Ab (20OnM and 10 μM, respectively, middle) or CS-E Ab alone (10 μM, right). In Figure 18B, the inhibitory effect of CS-E polysaccharides (CS-E poly) is blocked by the CS-E antibody in CGNs. P7 rat CGNs are grown for 24 hours on CS-E (1 μg/ml) in the presence of the CS-E antibody (CS-E Ab; 10 μg/ml). Digestion of CS-E polysaccharides with chondroitinaseABC (CHase) results in a small extent of residual inhibition, which is completely blocked by the CS-E antibody.
[0037] Figure 19: illustrates immunostaining of lesioned rat cortex and spinal cord with the anti-CS-E antibody. Specifically, sections from rat brains with cortical lesions at 1 day, 3 days, and 7 days post lesion were
immunostained with the CS-E antibody. Increased immunostaining around the lesion at all three time points was recorded. Levels of staining appeared highest at 3 days post-lesion. Immunostaining was also assessed 2 days following a dorsal funiculus lesion of the rat spinal cord. As with cortical lesions, there was a general increase in immunostaining in the lesion margin, and some cells around the lesion expressed CS-E at a fairly high level. Some cells in the gray matter also stained for CS-E, but not as intensely as those near the lesion. Dorsal and ventral white matter also stained for CS-E in a pattern that resembled neurofilament expression. These results demonstrate that the CS-E sulfation motif is upregulated shortly after brain or spinal cord injury in vivo. These findings also suggest that the time course for treating with the CS-E antibody should likely be early, given the rapid increase in CS-E expression within 1-2 days post injury.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
[0039] As used in the specification and claims, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise.
[0040] The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g. axon growth. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, or the physical delivery system in which it is carried.
[0041] As used herein, "treatment" or "treating," or "palliating" or "ameliorating" is used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant reduction, eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the reduction eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a
particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
[0042] A "therapeutic effect," as used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0043] The terms "co-administration," "administered in combination with," and their grammatical equivalents, as used herein, encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
[0044] The terms "antagonist" and "inhibitor" are used interchangeably, and they refer to a compound having the ability to inhibit a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the terms "antagonist" and "inhibitors" are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g. bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition. A preferred biological activity inhibited by an antagonist is associated with the development, or growth, of a neuron.
[0045] The term "agonist" as used herein refers to a compound having the ability to initiate or enhance a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the term "agonist" is defined in the context of the biological role of the target polypeptide. While preferred agonists herein specifically interact with (e.g. bind to) the target, compounds that initiate or enhance a biological activity of the target polypeptide by interacting with other members of the signal transduction pathway of which the target polypeptide is a member are also specifically included within this definition.
[0046] As used herein, "agent", "binding agent", or "biologically active agent" refers to a biological, pharmaceutical, or chemical compound or other moiety. Non-limiting examples include simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound. Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures. In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.
[0047] "Signal transduction" is a process during which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response. A modulator of a signal transduction pathway refers to a compound which modulates the activity of one or more cellular proteins mapped to the same specific signal transduction pathway. A modulator may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.
[0048] "Subject" refers to an animal, such as a mammal, for example a human. The methods described herein can be useful in both human therapaeutics and veterinary applications. In some embodiments, the patient is a mammal, and in some embodiments, the patient is human.
[0049] The term "in vivo" refers to an event that takes place in a subject's body.
[0050] The term "in vitro" refers to an event that takes place outside of a subject's body. For example, an in vitro assay encompasses any assay run outside of a subject assay. In vitro assays encompass cell-based assays in which cells alive or dead are employed. In vitro assays also encompass a cell-free assay in which no intact cells are employed.
[0051] As used herein, the term "chondroitin sulfate" or "CS" refers to a molecule comprised of one or more repeating units of one or more of the chondroitin sulfate structures provided in Figure 1. The term "chondroitin sulfate A" or "CS-A" refers to a molecule comprised of one or more repeating units of the CS-A structure provided in Figure 1. Additionally, the term "chondroitin sulfate C" or "CS-C" refers to a molecule comprised of one or more repeating units of the CS-C structure provided in Figure 1. And the term "chondroitin sulfate E" or "CS-E" refers to a molecule comprised of one or more repeating units of the CS-E structure provided in Figure 1.
II. Methods
[0052] The present invention provides methods for promoting neuronal regeneration in a subject. In one embodiment, the method includes the step of administering to said subject a pharmaceutical composition as provided herein comprising one or more compositions of the present invention that inhibit chondroitin sulfate (CS) mediated signaling, such as signaling via CS-A, CS-C, CS-E, or a combination thereof. An exemplary composition administered to a subject includes but is not limited to a composition comprising one or more binding agents that selectively bind CS-A, CS-C, CS-E, or a combination thereof. Other exemplary compositions to be used in the subject methods include but are not limited to agents that selectively bind to one or more of Nogo receptor (NgR), Nogo, Ephrin Receptor A4, Ephrin Receptor B3, Ephrin A3, p75NTR, oligodendrocyte-myelin glycoprotein (OMgp) or a soluble fragment thereof as provided herein.
[0053] Additional compositions that are capable of inhibiting CS mediated signaling include but are not limited to NgR, Nogo, Ephrin receptor B3, p75NTR, OMgp or a soluble fragment thereof, or a fusion or chimeric protein comprising a soluble fragment thereof. In still other cases, one can administer antagonists or inhibitors of downstream mediators of CS mediated signaling including inhibitors of MEK, epidermal growth factor receptor (EGFR), protein kinase C (PKC), RhoA, or other signaling molecules in the same or related pathways.
[0054] In yet other cases, siRNA or shRNA may be used to inhibit CS expression or downstream signaling events. For example, siRNA or shRNA may be used to silence expression of genes responsible for the biosynthesis or sulfation of CS (e.g., the GaINAc 4-sulfate 6-O-sulfotransferase that produces the CS-E sulfation pattern) or downstream mediators of CS signaling. In some cases, siRNA or shRNA may be used to silence expression of one or more of RhoA, MEK, NgR, Ephrin B3 receptor, or p75NTR, epidermal growth factor receptor (EGFR), protein kinase C (PKC) or other signaling molecules in the same or related pathways. Standard methods in the design of siRNA are known in the art (Elbashir et ah, Methods 26:199-213 (2002)). In general, a suitable siRNA is between about 10-50, or about 20-25 nucleotides, or about 20 -22 nucleotides. The target site typically has an AA dinucleotide at the 3' end of the sequence, as siRNA with a UU overhang can be more effective in gene silencing. The remaining nucleotides generally exhibit homology to the nucleotides 3' of the AA dinucleotide s. In general, the siRNA typically exhibits at least about 50% homology to the target sequence, preferably at least about 70%, about 80%, 90% or even 95% homology to the target sequence. Where desired, potential target sites are also compared to the appropriate genome database, such that target sequences may have fewer than 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or even 1% homology to other genes. The readily available public database on the NCBI server,
www.ncbi.nlm.nih.gov/BLAST is an example of a tool used to determine sequence homology. A public siRNA design tool is also readily available from the Whitehead Institute of Biomedical Research at MIT,
jura. wi.mit.edu/pubint/http://iona. wi.mit.edu/siRNAext/.
[0055] The siRNA can also take the form of a hairpin siRNA (i.e. shRNA). One may vary a number of known factors in designing a suitable siRNA. Such variables include the selection of siRNA target sequence, the length of the inverted repeats that encode the stem of a putative hairpin, the order of the inverted repeats, the length and composition of the spacer sequence that encodes the loop of the hairpin, and the presence or absence of 5 '-overhang can vary depending on the target and the predicted inverted region; all of which can be varied or customized according to standard procedures in the art. The stem can be 19 to 20 nucleotides long, preferably about 19, 21, 25, or 29 nucleotides long. The loop can range from 3 nucleotides to 23 nucleotides, with preference for loop sizes of about 3, 4, 5, 6, 7 and 9 nucleotides. Databases available to the public to aid in the selection and design of hairpin siRNA are also available, such as www.RNAinterference.org, and online design tools, for both hairpin siRNA and siRNA are available from commercial sites such as Promega and Ambion.
[0056] The methods provided herein are effective in inhibiting CS mediated signaling. Inhibition of CS mediated signaling such as CS-A mediated signaling, CS-C mediated signaling, or CS-E mediated signaling may be assayed by any methods known in the art as well as any methods provided herein. Non-limiting exemplary methods include assays for neuronal regeneration such as histochemical staining for neuronal specific markers as provided herein and further described in U.S. Patent Application Publication Nos. US20060177413 and US20070162989. Illustrative histochemical staining assays further include histochemical staining for neuronal specific markers, such as NgR, βlll tubulin, activin A, activin receptor Ia, activin receptor Ha, activin receptor Ib, activin receptor lib, axin 1, chondroitin sulfate 4, chondroitin sulfate E, 2',3 '-Cyclic Nucleotide 3 '-Phosphodiesterase (CNPase), Calbindin-D, Caspr2, Jagged 1, MAP2, Microtubule-Associated Proteins (MAPs), Myelin Basic Protein (MBP), NOTCHl, NOTCH2, NOTCH3, Nestin, Netrin-Gla, NeuroDl, NeuroD2, Neurofilament 200, Neurogenin 2, Neuronal Specific Enolase, Noggin, Receptor for Advanced Glycation Endproducts (RAGE), Reelin, Synaptophysin (SYP), Semaphorin 3A, Semaphorin 6A, Striatin, Survivin, Synapsin I, Synapsin II, Vimentin, Glutamic Acid
Decarboxylase 67 (GAD67), N-Cadherin, Neural Cell Adhesion Marker (NCAM), Tau, Neuropilin-1, Neuropilin-2, Peripherin, NG2, cerebroglycan, glycipan, Neurocan, Oligodendrocyte Marker Ol , Oligodendrocyte Marker O4, and Neurofibromin.
[0057] Alternatively, inhibition of CS mediated signaling such as CS-A mediated signaling, CS-C mediated signaling, or CS-E mediated signaling can be determined by (1) boundary crossing assays provided herein and as further described in M. Kaneko, T. Kubo, K. Hata, A. Yamaguchi, T. Yamashita, Neurosci. Lett. 423, 62 (2007); (2) growth cone collapse assays exemplified herein and as further described in U.S. Patent No. 6103232; and (3) neurite outgrowth assays exemplified herein and as further described in R. J. Gilbert et ah, MoI. Cell. Neurosci. 29, 545 (2005), R. Sivasankaran et al., Nat. Neurosci. 7, 261 (2004), M. Kaneko, T. Kubo, K. Hata, A. Yamaguchi, T. Yamashita, Neurosci. Lett. 423, 62 (2007), P. P. Monnier, A. Sierra, J. M. Schwab, S. Henke-Fahle, B. K. Mueller, MoI. Cell. Neurosci. 22, 319 (2003), U.S. Patent Application Publication No. US20090104166, and in U.S. Patent No. 6207639.
[0058] Additional procedures for assessing inhibition of CS mediated signaling including signaling via CS-A, CS- C, and/or CS-E mediated include assays for the inhibition of downstream mediators of CS mediated signaling. Exemplary methods include kinase assays for determining, e.g., MEK or EGFR kinase activity, immunoblots for detecting the phosphorylation level of downstream mediators in the CS sigaling pathway. Such downstream
mediators include but are not limited to MEK, EGFR or RhoA western or dot blots. In some cases, calcium influx assays (see, e.g. Science, VoI 259, Issue 5091, 80-83) or the measurement of GTPase activity of RhoA can also be performed (see, e.g., JBiomol Screen. 2009 Feb;14(2): 161-72. Epub 2009 Feb 4, and US Patent Application Publication No. US20060115870) to assess inhibition of CS mediated signaling. In addition, a wide variety of assays are available to assess protein or mRNA expression levels of these signaling molecules. Non-limiting examples include microarray assays, northern blot assays, SAGE assays, digital PCR assays, ELISA assays, pull down assays, radio-immuno-precipitation assays, histochemical staining, and western blot assays.
[0059] Inhibition of CS mediated signaling may further be evidenced by inhibition of binding of one or more of CS-A, CS-C, or CS-E to cell surface or extracellular receptors. Exemplary methods include pull down assays such as biotin pull down assays, ELISA, surface plasmon resonance assays, fluorescence activated cell sorting assays, and fluorescence resonance energy transfer assays. These CS binding assays may be performed on intact cells expressing one or more of p75NTR, NgR, Ephrin receptor Al, Ephrin receptor A2, Ephrin receptor A3, Ephrin receptor A4, Ephrin receptor A5, Ephrin receptor A6, Ephrin receptor A7, Ephrin receptor A8 or Ephrin receptor B3. Alternatively, these binding assays may be performed on purified protein or in cell or cell membrane extracts. These binding assays may further be performed in the presence of suspected modulators, antagonists, enhancers or agonists of the CS:receptor interaction. Theses modulators may include ephrins, ligands that activate Ephrin receptors, including but not limited to, Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin Bl, Ephrin B2 and Ephrin B3.
[0060] The methods of the present invention further provide for administering one or more of the compositions provided herein in a physiological acceptable carrier. In some embodiments, the compositions of the present invention may be administered as a pharmaceutical composition comprising a physiologically acceptable carrier and an agent that inhibits CS mediated signaling (e.g. CS-E mediated signaling), mitigates CS-mediated neuronal growth inhibition, or promotes neuronal regeneration or neurite outgrowth. In some cases, the agent that mitigates CS- mediated neuronal growth inhibition is a CS polysaccharide binding agent, such as an anti-CS antibody. In some cases, the CS polysaccharide binding agent selectively binds one or more of CS-A, CS-C, or CS-E. In some cases, the CS polysaccharide binding agent selectively binds CS-E, such as an anti-CS-E antibody. The pharmaceutical composition may comprise any of the binding agents provided herein such as anti-CS antibodies including anti-CS- E antibodies. The compositions provided herein may further be administered in a physiologically acceptable carrier such as any of the carrier formulations provided herein, or any other physiological acceptable carrier known in the art for administering macromolecular or small molecule binding agents of the present invention.
[0061] Therapeutic formulations of the binding agent of the present invention are prepared for storage by mixing the binding agent having the desired degree of purity with optional physiologically acceptable-carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including
glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as Tween, Pluronics™ or polyethylene glycol (PEG).
[0062] The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
[0063] The active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly- (methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0064] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the binding agent of the present invention, which matrices are in the form of shaped articles, e.g., films, or
microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2- hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat No. 3,773,919), copolymers of L- glutamic acid and γ-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated binding agents remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 370C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S— S bond formation through thio- disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
[0065] The methods provided herein further provide for administering a pharmaceutical composition of the present invention to a subject. The pharmaceutical compositions of the present invention may be administered by any suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary, intrathecal, and intranasal, and intralesional administration. Parenteral infusions include intramuscular, intrathecal, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In addition, the binding agents of the present invention may suitably be administered by pulse infusion, particularly with declining doses of the binding agent of the present invention. In some cases, the dosing is given by injections, such as intravenous, intrathecal, or subcutaneous injections, depending in part on whether the administration is brief or chronic. In other cases, the dosing is provided by a pump such as a mini-osmotic pump for long term delivery of the pharmaceutical composition, see e.g. US Patent No. 3995631, 4320758, and 7335193.
[0066] The binding agents and pharmaceutical compositions of the invention are particularly useful for parenteral administration, i.e., subcutaneously, intrathecally, intramuscularly or intravenously. The compositions for parenteral
administration will commonly comprise a solution of a binding agent such as an antibody or fragment thereof of the invention or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be employed, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc. The concentration of the antibody or fragment thereof of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight, and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected.
[0067] A pharmaceutical composition of the invention for intramuscular injection can be prepared to contain about 1 ml sterile buffered water, and about 50 mg of an antibody or fragment thereof of the invention. Similarly, a pharmaceutical composition of the invention for intravenous infusion could be made up to contain about 250 ml of sterile Ringer's solution, and 150 mg of a binding agent such as an antibody or fragment thereof of the invention. Actual methods for preparing parenterally administrable compositions are well known or will be apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference herein.
[0068] The pharmaceutical compositions of the invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with many protein, peptide, small molecule, and nucleic acid based binding agents and art-known lyophilization and re constitution techniques can be employed.
[0069] Depending on the intended result, the pharmaceutical composition of the invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a patient already suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. In prophylactic applications, compositions containing the present binding agents or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.
[0070] Single or multiple administrations of the pharmaceutical compositions can be carried out with dose levels and patterns being selected by the treating physician. In any event, the pharmaceutical composition of the invention should provide a quantity of the binding agents (or fragments thereof) of the invention sufficient to effectively treat the patient.
[0071] For the prevention or treatment of disease, the appropriate dosage of the one or more binding agents of the present invention will depend on the type of disease to be treated, the severity and course of the disease, whether the binding agent of the present invention is administered for preventive or therapeutic purposes, previous therapy, the patient clinical history and response to the binding agent of the present invention, and the discretion of the attending physician. The binding agent of the present invention may be suitably administered to the patient at one time or over a series of treatments.
[0072] Depending on the type and severity of the neural injury or disease, about 1 μg/kg to 15 mg/kg (e.g., 0.1-20 mg/kg) of the binding agent of the present invention is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired
neural growth occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. Dosages may begin to be administered within 1, 2, 3, 4, 5, 6, 7 or more days post injury.
[0073] The pharmaceutical composition comprising an inhibitor of CS mediated signaling such as a binding agent of the present invention may be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "therapeutically effective amount" of the binding agent to be administered may be governed by such considerations, and is the minimum amount necessary to promote neural growth either in vivo or in vitro. The binding agent need not be, but may optionally be formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of the binding agent present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.
[0074] In some embodiments, the pharmaceutical composition, binding agent and/or host cell of the present invention may be used to prevent or treat a neural injury or a neurodegenerative disease in a mammal. The mammal selected from the group consisting of a human, non-human primate, rodent, dog, cat, horse, cow, pig, sheep, rabbit, guinea pig, or goat. Subjects in need thereof may present, suffer from, be suspected of suffering from, or be susceptible to any one of a number of possible neural injuries or neurodegenerative diseases such as any of the injuries, diseases or conditions provided herein including but not limited to optic nerve injury, spinal cord injury, motor nerve injury, cholinergic neuron injury, blunt trauma, severing of a nerve, nerve fiber, or nerve tissue, or injuries due to environmentally, biologically (e.g. viral infection), physically, or chemically (e.g. nerve agent, or neurotoxin) induced trauma. Subjects in need thereof may present, suffer from, be suspected of suffering from, or be susceptible to any one of a number of possible neural injuries or neurodegenerative diseases such as any of the injuries, diseases or conditions provided herein including but not limited to Adrenoleukodystrophy (ALD), Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjόgren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cerebral palsy, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial Fatal Insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive Supranuclear Palsy, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, Toxic encephalopathy, or any combination thereof.
[0075] The methods of the present invention further provide for contacting one or more of the pharmaceutical compositions of the present invention with one or more of extracellular matrix components or neuronal cells.
Extracellular matrix components that may be contacted with a pharmaceutical composition of the present invention according to the methods of the present invention include but are not limited to proteoglycans such as CSPGs (e.g.
CS-A, CS-C, CS-E), heparan sulfate, and keratan sulfate; non-proteoglycan polysaccharides such as hyaluronic acid; protein fibers such as collagen and elastin; cell surface proteins such as fibronectin and laminin; and enzymes such as urokinase plasminogen activator and matrix metalloproteinases. Neuronal cells that may be contacted with a pharmaceutical composition of the present invention according to the methods of the present invention include but are not limited to dopaminergic neurons, cortical neurons, cholinergic neurons, GABAergic neurons, glutamatergic neurons, dopaminergic neurons, serotonergic neurons, peripheral neurons, autonomic neurons, motor neurons, sensory neurons, spinal cord neurons, interneurons, unipolar neurons, bipolar neurons, multipolar neurons, Basket cells, Betz cells, Medium spiny neurons, Purkinje cells, Pyramidal cells, Renshaw cells, Granule cells, and anterior horn cells.
[0076] In one aspect, the present invention provides a method of producing a CS binding agent such as an agent that selectively binds one or more of CS-A, CS-C, or CS-E such as anti-CS-A, anti-CS-C, or anti-CS-E antibody, comprising culturing a host cell containing an isolated polynucleotide encoding an antibody of the present invention under conditions suitable for expression of the subject antibody. In some embodiments, the present invention encompasses a culture medium comprising a host cell disclosed herein. In other embodiments, the present invention further includes a culture fermentor comprising a plurality of host cells of the invention in a culture medium.
[0077] Fermentation is a standard process well known in the relevant art for the breakdown and re-assembly of biochemicals and biological molecules including proteins for industry, often in aerobic growth conditions. A fermentor or a bioreactor as used herein refers to an apparatus that maintains optimal conditions for the growth of microorganisms, e.g. host cells of the present invention, used in large-scale or small-scale fermentation and in the commercial production of biological macromolecules including but not limited to proteins, for example, antibodies, NgR, p75NTR, Ephrin B3 receptor, Nogo, OMgp, or fragments thereof. Fermentation chambers may be used to produce these antibodies on a large scale. In some embodiments, the binding agent of the present invention can be produced in a culture fermentor.
III. Compositions
[0078] The present invention provides one or more compositions for promoting neuronal growth or regeneration in a subject. In some embodiments, the compositions promote neuronal growth or regeneration by inhibiting CS- mediated signaling. For example, these compositions may comprise binding agents that selectively bind to CS proteoglycans or to CS proteoglycan receptors, or compositions that selectively inhibit signaling events downstream of CS proteoglycan binding to cell surface or extracellular proteins. In some embodiments, the present invention provides binding agents that selectively bind to one or more of CS-A, CS-C, or CS-E. In some embodiments, binding agents that selectively bind to one or more of CS-A, CS-C, or CS-E reduce or eliminate the inhibitory effect of said CS proteoglycans on neuronal growth or regeneration. For example, the binding agents may sequester these proteoglycans from binding to an endogenous receptor, thereby preventing the generation of an inhibitory signal in a neuron. In some cases, the binding agents that selectively bind to CS-E may reduce or eliminate the inhibitory effect of said CS proteoglycans on neuronal growth or regeneration.
[0079] Selective binding agents are agents that bind to a substrate, receptor or antigen with an affinity, or avidity for that substrate, receptor or antigen that is greater than for another substrate, receptor, or antigen. In some embodiments a binding agent that selectively binds CS exhibit an affinity, or avidity to CS that is greater than the affinity, or avidity of that agent for a glycan that is not CS such as for example heparan sulfate or for a molecule that is not a proteglycan such as a protein or peptide. In some embodiments, a binding agent of the present invention
selectively bind one or more of CS-A, CS-C, or CS-E. Such binding agents that selectively bind one or more of CS- A, CS-C, or CS-E, may exhibit a greater affinity or avidity for one or more of CS-A, CS-C, or CS-E than that agent exhibits for other CS molecules, or than that agent exhibits for non-CS molecules or a combination thereof. For example, a binding agent of the present invention may selectively bind CS-A and exhibit reduced or undetectable binding to CS-C or CS-E or a combination thereof. Alternatively, a binding agent of the present invention may selectively bind CS-C and exhibit reduced or undetectable binding to CS-A or CS-E or a combination thereof. In still other cases, a binding agent of the present invention may selectively bind CS-E and exhibit reduced or undetectable binding to CS-A or CS-C or a combination thereof. In yet other embodiments, a binding agent of the present invention may selectively bind CS-E (for example) and exhibit reduced or undetectable binding to other, non CS, molecules. In some embodiments, selective binding to one or more of CS-A, CS-C, or CS-E may be assayed by the use of a carbohydrate array as provided herein. Other selective binding agents of the present invention include binding agents that selectively bind to CS receptors such as CS-E receptors including but not limited to NgR or P75
NTR
[0080] In some embodiments, selective binding agents are provided that bind to one or more of CS-A, CS-C, or CS-E (e.g. CS-E) or a combination thereof with a high affinity. For example, selective binding agents are provided that bind CS-E with an affinity (e.g. Kd) greater than about 10OnM, 75nM, 50 nM, 4OnM, 3OnM, 2OnM, 1OnM, 5nM, 4nM, 3nM, 2nM, or greater than about InM. By "greater than" is meant with a stronger affinity. By way of example an affinity (e.g. Kd) of 1OnM may be considered greater than an affinity of 5OnM. In some cases, selective binding agents are provided that bind CS (e.g. CS-E) with an affinity between about IpM and about 100OnM, between about IpM and about 75OnM, IpM and about 50OnM, IpM and about 25OnM, IpM and about 10OnM, IpM and about 5OnM, IpM and about 25nM, IpM and about 1OnM, lOpM and about 1OnM, 2OpM and about 1OnM, 5OpM and about 1OnM, 5OpM and about 5nM, or about IpM, 2pM, 3pM, 5pM, lOpM, 2OpM, 4OpM, 5OpM, 10OpM, 15OpM, 20OpM, 30OpM, 50OpM, 75OpM, InM, 2nM, 4nM, 4.3nM, 5nM, 1OnM, 2OnM, 3OnM, 4OnM, 5OnM, 10OnM, 20OnM. 30OnM, 40OnM, 50OnM, 75OnM or 100OnM.
[0081] In other embodiments, selective binding agents are provided that bind CS-E and inhibit the binding of CS- E to other targets, ligands or receptors such as Nogo, Nogo receptor (NgR), p75NTR, OMgp, or any fragment or soluble domain or derivative therefrom. For example, selective binding agents are provided that bind CS-E and inhibit binding to other targets, ligands or receptors with an inhibitor concentration (e.g. IC50) of less than 100OnM, less than 75OnM, less than 50OnM, less than 40OnM, less than 30OnM, less than 20OnM, less than 15OnM, less than 10OnM, less than 5OnM, less than 4OnM, less than 3OnM, less than 2OnM, or less than 10, 5, 4, 3, 2, or 1 nM. IC50 values can be assessed by directly measuring binding of CS-E to other targets, ligands, or receptors as provided herein, or by measuring down stream signaling events provided by CS-E as provided herein.
[0082] Exemplary binding agents include but are not limited to proteins such as antibodies, Nogo, Nogo receptor (NgR), p75NTR, OMgp, or any fragment or soluble domain or derivative therefrom which exhibits selective binding to one or more CS proteoglycans, such as for example one or more of CS-A, CS-C, or CS-E. Exemplary binding agents further include peptides such as for example the Nogo-66 antagonist peptide NEP 1-40. Exemplary binding agents further include aptamers such as polynucleic acids (DNA/RNA) or derivatives thereof including but not limited to pegylated or methylated derivatives which exhibit selective binding to one or more CS proteoglycans. Exemplary binding agents further include small molecules such as carbohydrate mimics that may bind to CS receptors such as for example P75 NTR, or NgR without triggering neuron growth inhibitory downstream signaling events. Exemplary binding agents still further include annexin domains (see e.g. U.S. Patent Application
Publication No. 20030133939), and avimers (see e.g. Silverman et al., Nat. Biotechnol. (2005), 23: 1556-1561). Additionally, exemplary binding agents include agents containing carbohydrates, lipids, amino acids, small organic or inorganic molecules, or combinations thereof.
[0083] Antibody binding agents of the present invention include but are not limited to full length mammalian or avian antibodies such as IgG, IgA, IgM, IgD, IgY, or IgE molecules which consist of one or more heavy chains and one or more light chains. The heavy and light chains are comprised of constant and variable regions. The variable regions contain complementarity determining regions (CDRs), which along with the surrounding framework regions provide the antigen binding regions of the antibodies. Antibodies may further include full length camel or shark antibodies which contain a heavy chain, but lack a light chain. Antibodies of the present invention may be polyclonal or monoclonal. In some cases, antibodies may be a mixture of two or more different monoclonal antibodies. Antibodies provided herein also include humanized antibodies in which one or more immunogenic portions of the antibody have been removed, or removed and replaced with human or human like sequences, or in which one or more immunogenic portions of the antibody have been masked or derivatized, such as by pegylation or glycosylation. Antibodies provided herein also include antibody fusion proteins in which the antibody or a portion thereof is fused covalently or non-covalently with a peptide. Antibody fusion proteins may provide enhanced detection, enhanced efficacy, or enhanced antibody-mediated cytotoxicity. The antibodies may also be conjugated with drugs, toxins or therapeutic radioisotopes. Bispecific antibodies including hybrid antibodies which bind to more than one antigen are also included. The subject antibodies encompass naked antibodies, chimeric antibodies, conjugated antibodies and antibody fragments, which may be monospecific or multispecific.
[0084] Antibodies may further include fragments or full length antibodies of the isolated antibody 2Dl 1-2A10 produced by a cell line deposited under ATCC accession number PTAl 0049 on May 5, 2009 and described in U.S. Pat. No. 7,745,584. Full length antibodies may comprise an isolated antibody comprising a heavy chain and a light chain, wherein said heavy chain comprises the three heavy chain complementarity determining regions (CDRs) of antibody 2Dl 1-2A10 that is produced by a cell line deposited under ATCC accession number PTAl 0049, and wherein said light chain comprises the three light chain CDRs of said antibody 2Dl 1-2A10, wherein the isolated antibody binds to a mammalian chondroitin sulfate E oligosaccharide comprising one or more disaccharides. Full length antibodies or fragments may also comprise one, two, or all three of the heavy and/or light chain CDRs of antibody 2Dl 1-2A10. Theses antibodies can be further modified to humanized antibodies with improved immunogenicity profile or properly according to methods known in the art and disclosed herein.
[0085] Antibodies may further include fragments of full length antibodies such as described in U.S. Pat. No. 6,833,441 including single chain antibodies, single chain Fv's, disulfide stabilized single chain Fv's, and coiled coil stabilized single chain Fv's. In some cases, single chain Fv's may comprise heavy and light chain variable regions. In other cases, single chain Fv's may comprise just a heavy chain variable region, such as a camel or a shark single chain Fv, or just a light chain variable region. Antibodies may further include Fab fragments which comprise a portion of the heavy chain and the light chain. Antibodies may further include minibodies such as described in U.S. Pat. No. 5,837,821, or affibodies such as described in U.S. Pat. No. 5,831,012.
[0086] The antibodies of the present invention may be monoclonal which refers to an antibody from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical and/or bind the same epitope(s), except for possible variants that may arise during production of the monoclonal antibody, such variants generally being present in minor amounts. Such monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target (e.g., CS-E), wherein the target-binding polypeptide
sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones or recombinant DNA clones.
[0087] It should be understood that the selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this disclosure. In contrast to polyclonal antibody preparations which typically include different antibodies directed against different determinants (e.g., epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, the monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler et al, Nature, 256:495 (1975); Harlow et al, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2" ed. 1988) ; Hammerling et al. , in: Monoclonal Antibodies and T-CeIl Hybridomas 563-681, (Elsevier, N. Y., 1981)), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), phage display technologies (see, e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al, J. MoI. Biol, 222:581- 597 (1991); Sidhu et al, J. MoI Biol. 338(2) :299-310 (2004); Lee et al, J.Mol.Biol 340(5): 1073-1093 (2004); Fellouse, Proc. Nat. Acad. ScL USA 101 (34). -12467-12472 (2004); and Lee et al J. Immunol. Methods 284(1- 2): 119-132 (2004)), and technologies for producing human or human-like antibodies in animals that have parts or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO
1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits et al, Proc. Natl. Acad Sci. USA, 90:2551 (1993); Jakobovits et al, Nature, 362:255-258 (1993); Bruggemann et al, Year in Immuno., 7:33 (1993); U.S. Pat. Nos. 5,545,806; 5,569,825; 5,591,669 (all of GenPharm); U.S. Pat. No. 5,545,807; WO 1997/17852; U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks et al, Bio/Technology, 10: 779-783 (1992); Lonberg et al, Nature, 368: 856-859 (1994); Morrison, Nature, 368: 812-813 (1994); Fishwild et al, Nature Biotechnology, 14: 845-851 (1996); Neuberger, Nature Biotechnology, 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol, 13: 65-93 (1995)).
[0088] Monoclonal antibodies herein include chimeric antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al, Proc. Natl. Acad. ScL USA, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc) and human constant region sequences.
[0089] A "chimeric polypeptide" or a "chimeric polynucleotide" as used herein refers to an artificially constructed protein or polynucleotide comprising heterologous amino acid sequences or heterologous nucleic acid sequences, respectively. Chimeric proteins are proteins created through the joining of two or more genes, or portions of two or more genes, which originally coded for separate proteins. Translation of this fusion gene results in a single
polypeptide with function properties derived from each of the original proteins. Such chimeric proteins are created artificially by recombinant DNA technology well known in the art.
[0090] The chimeric protein of the present invention is encoded by a heterologous nucleic acid sequence. As used herein, nucleic acid sequence is used interchangeably with polynucleotide, nucleotide, nucleotide sequence, nucleic acid and oligonucleotide. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non- coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, siRNA, shRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
[0091] The heterologous sequence for production of a subject binding agent may comprise a vector, which is a nucleic acid molecule, preferably self-replicating, which transfers an inserted nucleic acid molecule into and/or between host cells. Vectors may include those that function primarily for insertion of DNA or RNA into a cell, replication of vectors that function primarily for the replication of DNA or RNA, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions. An expression vector is a polynucleotide which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide(s). In some embodiments, an expression vector comprises a polynucleotide encoding a chimeric anti-CS-E antibody. The encoded antibody can be modified, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. Furthermore, amino acid refers to either natural and/or unnatural or synthetic amino acids, including but not limited to glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. Standard single or three letter codes are used to designate amino acids.
[0092] The polynucleotide sequence encoding a binding agent such as an antibody of the present invention can be expressed by a single or multiple vectors. The nucleic acid sequences can be arranged in any order in a single operon, or in separate operons that are placed in one or multiple vectors. Where desired, two or more expression vectors can be employed, each of which contains one or more heterologous sequences operably linked in a single operon. Linked refers to the joining together of two more chemical elements or components, by whatever means including chemical conjugation or recombinant means. Operably-linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter sequence is linked, or operably linked, to a coding sequence if the promoter sequence promotes transcription of the coding sequence.
[0093] While the choice of single or multiple vectors and the use of single or multiple promoters may depend on the size of the heterologous sequences and the capacity of the vectors, it will largely dependent on the overall yield of a given glycoprotein that the vector is able to provide when expressed in a selected host cell. In some instances, two-operon expression system provides a higher yield of glycoproteins. The subject vectors can stay replicable episomally, or as an integral part of the host cell genome.
[0094] The heterologous sequence encoding a binding agent such as an antibody of the present disclosure can be under the control of a single regulatory element. In some cases, the heterologous nucleic acid sequences are regulated by a single promoter. In other cases, the heterologous nucleic acid sequences are placed within a single operon. In still other cases, the heterologous nucleic acid sequences are placed within a single reading frame.
[0095] Preparation of the subject nucleic acids can be carried out by a variety of routine recombinant techniques and synthetic procedures. Standard recombinant DNA and molecular cloning techniques are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press : Cold Spring Harbor, (1989) (Maniatis) and by T. J. Silhavy, M. L. Bennan, and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y. (1984) and by Ausubel, F. M. et al, Current Protocols in Molecular Biology, pub. By Greene Publishing Assoc, and Wiley- Interscience (1987). Briefly, the subject nucleic acids can be prepared genomic DNA fragments, cDNAs, and RNAs, all of which can be extracted directly from a cell or recombinantly produced by various amplification processes including but not limited to PCR and rt-PCR.
[0096] Regulatory elements include, for example, promoters and operators, which can also be engineered to increase the expression of one or more heterologous sequences encoding a glycoprotein. A promoter is a sequence of nucleotides that initiates and controls the transcription of a nucleic acid sequence by an RNA polymerase enzyme. An operator is a sequence of nucleotides adjacent to the promoter that functions to control transcription of the desired nucleic acid sequence. The operator contains a protein-binding domain where a specific repressor protein can bind. In the absence of a suitable repressor protein, transcription initiates through the promoter. In the presence of a suitable repressor protein, the repressor protein binds to the operator and thereby inhibits transcription from the promoter.
[0097] In some embodiments of the present disclosure, promoters used in expression vectors are inducible. In other embodiments, the promoters used in expression vectors are constitutive. In some embodiments, one or more nucleic acid sequences are operably linked to an inducible promoter, and one or more other nucleic acid sequences are operably linked to a constitutive promoter. Non-limiting examples of suitable promoters for use in eukaryotic host cells include, but are not limited to, a CMV immediate early promoter, an HSV thymidine kinase promoter, an early or late SV40 promoter, LTRs from retroviruses, and a mouse metallothionein-I promoter.
[0098] The genes in the expression vector typically will also encode a ribosome binding site to direct translation (that is, synthesis) of any encoded mRNA gene product. Other regulatory elements that may be used in an expression vector include transcription enhancer elements and transcription terminators. See, for example, Bitter et al, Methods in Enzymology, 153:516-544 (1987).
[0099] An expression vector may be suitable for use in particular types of host cells and not others. One of ordinary skill in the art, however, can readily determine through routine experimentation whether a particular expression vector is suited for a given host cell. For example, the expression vector can be introduced into the host organism, which is then monitored for viability and expression of any genes contained in the vector.
[00100] The expression vector may also contain one or more selectable marker genes that, upon expression, confer one or more phenotypic traits useful for selecting or otherwise identifying host cells that carry the expression vector. Non-limiting examples of suitable selectable markers for eukaryotic cells include dihydrofolate reductase and neomycin resistance.
[00101] The subject vectors can be introduced into a host cell stably or transiently by variety of established techniques. For example, one method involves a calcium chloride treatment wherein the expression vector is introduced via a calcium precipitate. Other salts, for example calcium phosphate, may also be used following a similar procedure. In addition, electroporation (that is, the application of current to increase the permeability of cells to nucleic acids) may be used. Other transformation methods include microinjection, DEAE dextran mediated transformation, and heat shock in the presence of lithium acetate. Lipid complexes, liposomes, and dendrimers may also be employed to transfect the host cells.
[00102] Upon introduction of the heterologous sequence into a host cell, a variety of methods can be practiced to identify the host cells into which the subject vectors have been introduced. One exemplary selection method involves subculturing individual cells to form individual colonies, followed by testing for expression of the desired protein prodcut. Another method entails selecting host cells containing the heterologous sequence based upon phenotypic traits conferred through the expression of selectable marker genes contained within the expression vector. Those of ordinary skill can identify genetically modified host cells using these or other methods available in the art.
[00103] For example, the introduction of various heterologous sequences of the disclosure into a host cell can be confirmed by methods such as PCR, Southern blot or Northern blot hybridization. For example, nucleic acids can be prepared from the resultant host cells, and the specific sequences of interest can be amplified by PCR using primers specific for the sequences of interest. The amplified product is subjected to agarose gel
electrophoresis, polyacrylamide gel electrophoresis or capillary electrophoresis, followed by staining with ethidium bromide, SYBR Green solution or the like, or detection of DNA with a UV detection. Alternatively, nucleic acid probes specific for the sequences of interest can be employed in a hybridization reaction. The expression of a specific gene sequence can be ascertained by detecting the corresponding mRNA via reveres-transcription coupled PCR, Northern blot hybridization, or by immunoassays using antibodies reactive with the encoded gene product. Exemplary immunoassays include but are not limited to ELISA, radioimmunoassays, and sandwich immunoassays.
[00104] Furthermore, the introduction of various heterologous sequences of the disclosure into a host cell can be confirmed by the enzymatic activity of an enzyme that the heterologous sequence encodes. The enzyme can be assayed by a variety of methods known in the art. In general, the enzymatic activity can be ascertained by the formation of the product or conversion of a substrate of an enzymatic reaction that is under investigation. The reaction can take place in vitro or in vivo.
[00105] The subject binding agents such as an antibody of the present invention can be produced by any methods known in the art. For instance, the subject antibody can be produced heterologously by expressing the antibody in a host cell. Suitable host cells can be used to make hybridomas for producing the subject antibodies of the present invention. A mouse or other appropriate host animal, (such as a hamster, goat, sheep, dog, horse, pig, rat, rabbit, dog, cat, or gerbil, amongst others) can be immunized as to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)).
[00106] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma
cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
[00107] In one embodiment, myeloma cells are used that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. In some embodiments the myeloma cell lines are murine myeloma lines, (including, but not limited to, MOPC-21, MPC-11, SP-2 or X63-Ag8-653 cells), human myeloma cell lines (including, but not limited to, Karpas 707H, RPMI 8226, 8226 AR/NIP4-1, KM-2R, or U-266), or rat myeloma cell lines (including, but not limited to, YB2/3.O.Ag.2O, YB2/0, Y3- Agl.2.3, IR983F).
[00108] Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. The binding specificity of monoclonal antibodies produced by hybridoma cells can be determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis, (see for example, Munson et ah, Anal. Biochem. 107:220 (1980)).
[00109] After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI- 1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
[00110] The monoclonal antibodies secreted by the subclones can then be suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[00111] In some embodiments, a monoclonal antibody can be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
[00112] Conventional recombinant techniques can be employed to generate polypeptides encoding the heavy and light chains of a subject anti-CS antibody. For example, messenger RNA (mRNA) coding for heavy or light chain is isolated from a suitable source, such as mature B cells or a hybridoma culture, is obtained by employing standard techniques of RNA isolation purification and optionally size based isolation. cDNAs corresponding to mRNAs coding for heavy or light chain are then produced and isolated using techniques known in the art, such as cDNA library construction, phage library construction and screening or RT-PCR using specific relevant primers. In some embodiments, the cDNA sequence may be one that is wholly or partially manufactured using known in vitro DNA manipulation techniques to produce a specific desired cDNA. The cDNA sequence can then be positioned in a vector which contains a promoter in reading frame with the gene and compatible with the low-modified host cell. Numerous plasmids that contain appropriate promoters, control sequences, ribosome binding sites, and transcription termination sites, and optionally convenient markers are known in the art, these include but are not limited to, vectors described in U.S. Pat. Nos. 4,663,283 and 4,456,748. In one embodiment, the cDNA coding for the light chain and that coding for the heavy chain may be inserted into separate expression plasmids. In
an alternative embodiment, the cDNA coding for the light chain and that coding for the heavy chain may be inserted together in the same plasmid, so long as each is under suitable promoter and translation control.
[00113] The expression vectors constructed above can then be used to transform a host cell. In some embodiments, the host cell is a wildtype host cell. In other embodiments, the host cell is modified, for example, contains one or more mutations. In one embodiment, the light and heavy chains may be transformed into separate modified host cell cultures, either of the same or of differing species. In an alternative embodiment, separate plasmids for light and heavy chain may be used to co-transform a single modified host cell culture. In another embodiment, a single expression plasmid containing both genes and capable of expressing the genes for both light and heavy chain may be transformed into a single modified host cell culture.
[00114] When heavy and light chains are coexpressed in the same host, the isolation procedure is designed so as to recover reconstituted antibody. This can be accomplished by conventional antibody purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[00115] In some embodiments, a monoclonal antibody purified by recombinant methods can be purified
(1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
[00116] As noted above, a subject binding agent such as an antibody can be a humanized antibody, such as a human chimeric antibody, or a human complementary determining region (CDR) grafted antibody. Humanized forms of non-human (e.g., mouse, rat, hamster, goat, sheep, horse, cattle or rabbit) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies are typically human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, goat, sheep, horse, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non- human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et ah, Nature 321:522-525 (1986); Riechmann et al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[00117] The term variable refers to certain portions of the variable domains differing extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is typically not evenly distributed throughout the variable domains of antibodies. It is usually concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FRs). The variable domains of native heavy and light chains each comprise four FRs, largely adopting a β-sheet
configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, Sequences of Proteins of Immunological Interest, 5' Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).
[00118] The term hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a CDR (e.g residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (HI), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (Ll), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (Hl), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and LeskJ. MoI Biol. 196:901-917 (1987)). "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.
[00119] A human chimeric antibody is an antibody which comprises an antibody heavy chain variable region (hereinafter referred to as "HV" or "VH", the heavy chain being "H chain") and an antibody light chain variable region (hereinafter referred to as "LV" or "VL", the light chain being "L chain"), both of an animal other than human, a human antibody heavy chain constant region (hereinafter also referred to as "CH") and a human antibody light chain constant region (hereinafter also referred to as "CL"). As the animal other than human, any animal such as mouse, rat, hamster, rabbit or the like can be used, so long as a hybridoma can be prepared there from.
[00120] A human chimeric antibody can be produced by obtaining cDNA's encoding heavy chain variable region (VH) and light chain variable region (VL) from a monoclonal antibody-producing hybridoma, inserting them into an expression vector for a host cell having genes encoding human antibody CH and human antibody CL to thereby construct a human chimeric antibody expression vector, and then introducing the vector into a low- fucosylation cell to express the antibody.
[00121] In regards to the heavy chain constant region (CH) of a human chimeric antibody, any CH can be used, so long as it is in the human immunoglobulin (hereinafter referred to as "hlg") class. In some embodiments, the CH belongs to the hlgG class or one of the subclasses belonging to the HgG class, such as hlgGl, hIgG2, hIgG3 and hIgG4. Likewise, in regards to the light chain constant region (CL) of human chimeric antibody, any CL can be used, so long as it belongs to the hlg class. In some embodiments, the light chain constant region (CL) of human chimeric antibody, belongs to the keppa class or lambda class.
[00122] A human CDR-grafted antibody can be produced by constructing cDNA's encoding variable regions in which CDR' s of VH and VL of an antibody derived from an animal other than human are grafted into CDR' s of VH and VL of a human antibody, inserting them into an expression vector for host cell having genes encoding human antibody CH and human antibody CL to thereby construct a human CDR-grafted antibody expression vector, and then introducing the expression vector into a modified host cell of the present disclosure to express the human CDR-grafted antibody.
[00123] Preferably the antibody of the present invention essentially retains the ability to bind antigen compared to the parental antibody. In some embodiments, the antibody of the present invention exhibits higher binding affinity to an antigen, for example, at least 1.1, 1.2, 1.3. 1.4, 1.5, 2, 3, 4, or 5 fold higher than a parental antibody. In other embodiments, the antibody of the present invention exhibits lower binding affinity to an antigen, for example, no less than 5%, 10%, 20%, 30%, 40%, or 50% of the binding affinity of a parental antibody to the antigen. The binding capability of the antibody of the present invention may be determined using techniques such as fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA), for example.
[00124] In some embodiments, the anti-CS antibody of the present invention encompasses any form of CS binding unit other than a full-length antibody, such as an anti-CS binding unit other than a full length antibody that selectively binds one or more of CS-A, CS-C, or CS-E. A vector encoding a recombinant protein (such as a plasmid, or virus) using techniques standard in the art can be introduced into a host cell and the recombinant antibody may be any antibody fragments, such as Fv, Fab, scFV or diabody fragments.
[00125] The Fv fragment is the minimum antibody fragment which contains a complete antigen- recognition and antigen-binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six hypervariable regions confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
[00126] The Fab fragment also contains the constant domain of the light chain and the first constant domain (CHl) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHl domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol group. F(ab').sub.2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[00127] Single-chain Fv (scFv) antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. In some embodiments the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). Antibody scFv fragments are described in WO93/16185; U.S. Pat. No. 5,571,894; and U.S. Pat. No. 5,587,458, which are hereby incorporated by reference in their entirety, and may be produced by the modified host cells of the present disclosure.
[00128] The term diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a VH domain connected to a VL domain in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, EP 404,097; WO 93/11161; and Hollinger et al, Proc. Natl. Acad. Sci USA, 90:6444-6448 (1993), which are hereby incorporated by reference in their entirety.In some embodiments, the anti-CS antibody provided herein such as an anti-CS-E antibody or fragment thereof is an inhibitory antibody. Inhibitory antibodies may inhibit one or more biological activities of the antigen to which the antibody binds. For example, an inhibitory
antibody can downregulate signal transduction of the corresponding antigen by inhibiting the activity of the antigen or inhibit expression of the antigen. In some embodiments, the antibody is a neutralizing antibody. A neutralizing antibody reduces or abolishes some biological activity of a soluble antigen or of a living microorganism, such as an infectious agent. Neutralizing antibodies may compete with the natural ligand or receptor for its antigen.
Host Cells
[00129] An anti-CS antibody of the present disclosure, such as an anti-CS antibody that selectively binds to one or more of CS-A, CS-C, or CS-E can be produced by a host cell. A host cell includes an individual cell, cell culture, or cell line. Host cells include progeny of a single host cell. A host cell can be transfected with a heterologous sequence of the present disclosure. Host cells may be prokaryotic or eukaryotic, such as bacterial cells, fungal cells, animal cells, insect cells, plant cells and the like. Host cells are preferably capable of glycosylation.
[00130] Examples of bacterial host cells include microorganisms belonging to the genus Escherichia,
Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas and the like. For example, bacterial host cells may include, but not be limited to, Escherichia coli XLl-Blue, XL2-Blue, DHl, MClOOO, KY3276, W1485, JM109, HBlOl, No. 49, W3110, NY49, G1698, or TBl. Other bacterial host cells may include, but not be limited to, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Bacillus subtilis, Bacillus amyloliquefaciens, Brevibacterium ammoniagenes, Brevibacterium immariophilum ATCC 14068, Brevibacterium saccharolyticum ATCC 14066, Brevibacterium flavum ATCC 14067, Brevibacterium
lactofermentum ATCC 13869, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 13869, Corynebacterium acetoacidophilum ATCC 13870, Microbacterium ammoniaphilum ATCC 15354, Pseudomonas putida, Pseudomonas sp. D-0110 and the like.
[00131] Yeast host cells may include microorganisms belonging to the genus Saccharomyces,
Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwanniomyces, Pichia, Candida and the like, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans,
Schwanniomyces alluvius, Candida utilis and the like.
[00132] Other examples of eukaryotic cells include animal cells such as mammalian cells. For example, host cells preferably include, but are not limited to, Chinese hamster ovary cells (CHO) or monkey cells, such as COS cells. The CHO cells may include, but not be limited to, CHO/dhfr" or CHO/DG44 cells. The Chinese hamster ovary tissue-derived CHO cell includes any cell which is a cell line established from an ovary tissue of Chinese hamster (Cricetulus griseus). Examples include CHO cells described in documents such as Journal of Experimental Medicine, 108, 945 (1958); Proc. Natl. Acad. ScL USA, 60 , 1275 (1968); Genetics, 55, 513 (1968); Chromosoma, 41, 129 (1973); Methods in Cell Science, 18, 115 (1996); Radiation Research, 148, 260 (1997); Proc. Natl. Acad. ScL USA, 77, 4216 (1980); Proc. Natl. Acad. ScL, 60, 1275 (1968); Cell, 6, 121 (1975); Molecular Cell Genetics, Appendix I, II (pp. 883-900); and the like. In addition, CHO-Kl (ATCC CCL-61), DUXBI l (ATCC CCL-9096) and Pro-5 (ATCC CCL-1781) registered in ATCC (The American Type Culture Collection) and a commercially available CHO-S (Life Technologies, Cat # 11619) or sub-cell lines obtained by adapting the cell lines using various media can also be exemplified.
[00133] In an alternative embodiment the parent cell line is derived from a lymphocytic lineage cell line, such as a B cell line. The host cell may be from cell lines used in hybridoma production. They can be myeloma
cells, such as from murine myeloma lines, such as, but not limited to, MOPC-21, MPC-11, NSO, SP-2, Sp2/0, S 194, and X63-Ag8-653 cells; human myeloma cell lines , such as, but not limited to, Namalwa, Karpas 707H, RPMI 8226, 8226 AR/NIP4-1, KM-2R, and U-266; or rat myeloma cell lines, such as, but not limited to, YB2/0, YB2/3.O.Ag.2O, Y3- Agl.2.3, IR983F. Cell lines, such as HeLa, HEK-293, NIH3T3, COS, CHO, NSO, PER.C6, K562, Ll.2, JY, BHK, K562, 293F, 3T3, and Jurkat may also be used in the present disclosure.
[00134] Examples of insect host cells include Spodoptera frugiperda ovary cells, such as Sf9 and Sf21
(Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York (1992)); a Trichoplusia ni ovary cell such as High 5 (manufactured by Invitrogen); and the like. Examples of plant host cells include plant cells of tobacco, potato, tomato, carrot, soybean, rape, alfalfa, rice, wheat, barley and the like.
[00135] In some embodiments, the host cell is a non-lymphocytic cell. A lymphocyte is a type of white blood cell in the vertebrate immune system. Lymphocytes typically include T cells, B cells and natural killer (NK) cells. A non-lymphocytic cell encompasses any type of cell that is not a lymphocyte. The host cell of the invention may have a species origin selected from the group consisting of human, mouse, rat, fruit fly, worm, yeast and bacterium. The host cell may be derived from a suitable tissue including but not limited to blood, muscle, nerve, brain, heart, lung, liver, pancreas, spleen, thymus, esophagus, stomach, intestine, kidney, testis, ovary, hair, skin, bone, breast, uterus, bladder, spinal cord, or various kinds of body fluids. The host cells producing the subject antibodies may be derived from any developmental stage including embryo and adult stages, as well as developmental origin such as ecotodermal, mesodermal, and ectodermal origin. In some embodiments, the host cells are CHO, NSO, SP2/0, HEK293, PER.C6 or YB2/0 cells.
IV. Examples
Example 1: Dorsal Root Ganglion (DRG) neurite outgrowth assay
[00136] Neurite outgrowth assays using dorsal root ganglions are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth. Acid-treated, 15-mm round German glass coverslips (Carolina Biologicals) are coated with poly-DL-ornithine (P- Orn; Sigma-Aldrich) in pH 6.5-8.5 borate buffer (approximately 0.5 mg/ml) for about 2 hr at about 37 0C and approximately 5% CO2. The coverslips are then washed with sterile water and dried in air. CSPGs (approximately 1 μg/ml; Chemicon), CSPGs treated with chondroitinase ABC (Seikagaku; 1-40 mU ChABC per μg CSPG incubated for about 2 hr at approximatley 370C; complete cleavage verified by SDS-PAGE), polysaccharides enriched in the CS-A, CS-C or CS-E sulfation motifs (approximately 1 μg/ml based on glucuronic acid content; Seikagaku super special grade, purified from sturgeon notochord, shark cartilage and squid cartilage, respectively), or synthetic gly copolymers (approximately 1 μg/ml) are added to the coated coverslips for about 2 hr at 37 0C and 5% CO2. DRGs are dissected from day 4-10 chick embryos, incubated in 0.0125%-0.25% trypsin w/ EDTA for about 15 min at 37 C, triturated to dissociate to single cell suspensions, and grown on the coverslips coated with the above- mentioned substrata. Cells are grown in a growth medium composed of DMEM/F12, 10% horse serum, approximately 50 ng/ml NGF (Sigma-Aldrich), and Insulin-Transferrin-Selenium-X Supplement (Invitrogen) for about 12 hr. In the case of antibody blocking experiments, approximately 0.1 mg/ml of the anti-CS-E (7), anti-CS-A (2H6; Seikagaku), or IgG control antibody (Pierce) is added into the medium at time T=O and co-incubated with cells for about 12 hr. Cells are fixed in paraformaldehyde (PFA) with 5-15% sucrose, immunostained using a rabbit
anti-βlll tubulin antibody (Sigma) and subsequently an Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (Pierce), imaged using a Nikon TE2000-S fluorescent microscope equipped with Metamorph software, and quantified using the NIH software Image J. The data are statistically analyzed using the one-way ANOVA; n = 50- 200 cells per experiment. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth.
Example 2: Growth cone collapse assay
[00137] Growth cone collapse assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth. 8-Well Lab-Tek® II CC2™ Slides (Electron Microscopy Sciences) are coated with P-Orn in pH 6.5-8.5 borate buffer for about 2 hr at 37 0C and 5% CO2, then coated with laminin (approximately 10 μg/ml; Invitrogen) for about 2 hr at 37 0C and 5% CO2. DRG explants are dissected from E6-10 chick embryos and grown on the P-Orn/laminin substratum for about 24 hr, treated with the indicated polysaccharides (at approximately 10 μg/ml) or glycopolymers (at approximately 10 μg/ml) for about 30 min, fixed in PFA with 5-15% sucrose, stained using rhodamine phalloidin (Pierce), and imaged using a Nikon TE2000-S fluorescent microscope. The percentage of collapsed growth cones is expressed as the percentage ratio of the number of collapsed growth cones over the number of total growth cones (including collapsed and uncollapsed). P-values are determined using one-way ANOVA; n = 50-100 growth cones per experiment, using results from at least five independent experiments. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at preventing growth cone collapse.
Example 3: Boundary crossing assay
[00138] Boundary crossing assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth. CS polysaccharides at various concentrations mixed with Texas Red (at approximately 0.5 mg/ml; Invitrogen) are spotted at the center of P-Orn-coated coverslips (about 5 μl) for about 2 hr at 370C and 5% CO2. Cerebella are dissected from P5-9 Sprague Dawley rats, incubated in 0.0125%-0.25% trypsin w/ EDTA for about 15 min at 370C, triturated to dissociate to single cell suspensions, purified on a discontinuous Percoll gradient, and cultured on the coated coverslips for about 48 hr. Cells are fixed in PFA with 5-15% sucrose, immunostained using an anti-β tubulin III antibody, imaged using a Nikon TE2000-S fluorescent microscope and Metamorph software, and quantified using the NIH software Image J. Axons growing toward the boundary and within 10 μm distance of the boundary are evaluated. The percentage of axons that cross the boundary over the total axons is quantified. P-values are determined using one-way ANOVA; n = 30-50 axons per experiment. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting an increase in the number of axons that cross the boundary.
Example 4: Cerebellar granule neuron (CGN) neurite outgrowth assay
[00139] CGN neurite outgrowth assays are useful for assaying the effects of the methods and compositions of the present invention in promoting neuronal regeneration or neurite outgrowth or in reducing or eliminating CS-E mediated signaling such as for example CS-E mediated inhibition of neuronal growth. Nitric acid-treated, 15-mm round German glass coverslips are coated with P-Orn in pH 6-8.5 borate buffer (at approximately 50 μg/ml) for
about 1 hr at 37 0C and 5% CO2. CSPGs (at approximately 1 μg/ml) or polysaccharides enriched in the CS-A, CS- C, or CS-E sulfation motifs (at approximately 1 μg/ml) are coated on the P-Orn-coated coverslips overnight at 37 0C and 5% CO2. Cerebella from P5-9 Sprague Dawley rats are dissected, purified as described above, and cultured on the coated coverslips at a cell density of about 200 cells/mm2. Neurons are grown in DMEM/F12, 1% FBS, and Nl supplement for about 24 hr.
[00140] In one example, inhibitors against MEK (PD98059, 25 μM; Calbiochem), EGFR (AG1478, 15 nM; Calbiochem), ROCK (Y27632, 5 μM; Calbiochem) and JNK (JNK Inhibitor II, 10 μM; Calbiochem) are added in solution at the start of culturing, and neurons are grown for 24 hr. For neurite outgrowth experiments from p75 knockout mice, cerebella from P5-7 mice, either C57BL/6 wild-type or p75-/- knockout mice, are dissected and purified as described above. Neurons are plated at a density of 200-300 cells/mm and cultured for about 24 hr. Cells are then fixed in 4% PFA/ 10% sucrose, immunostained with neuronal specific anti-class III β-tubulin antibody (TUJl; Covance), and evaluated for neurite outgrowth. Neurons are imaged using a Nikon TE2000-S fluorescent microscope and quantified using the NIH software Image J. Statistical analysis is performed using the one-way ANOVA; n = 50-200 cells per experiment. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth.
[00141] One of the proteins shown herein to specifically bind CS-E-enriched polysaccharides is the Eph receptor A4 (EphA4), suggesting that EphA4 is involved in CS-E signaling. In one example, CGN neurons from EphA4-deficient mice were examined for effects on neurite outgrowth. Mice were dissected and purified as described above. Neurons were plated, cultured, and fixed as described above and immunostained an anti-bill tubulin antibody. Neurons were imaged using a Nikon TE2000-S fluorescent microscope and quantified using the NIH software Image J. Statistical analysis is performed using the one-way ANOVA; n = 50-200 cells per experiment; p value < 0.02. Results show that CGN neurons from EphA4-deficient mice exhibit reduced inhibition of neurite outgrowth by CS-E as compared to control mice (Figure 17). Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth.
[00142] In another example, the results show that CS-E antibody blocks the inhibitory effects of CS-E polysaccharides on rat cerebellar granule neurons (Figure 18B). P7 rat CGNs are grown for 24 hours on CS-E (1 μg/ml) in the presence of the CS-E antibody (CS-E Ab; 10 μg/ml). The CS-E antibody completely blocks the inhibition of neurite outgrowth caused by CS-E and CSPGs. Digestion of CS-E polysaccharides with
chondroitinaseABC (CHase) results in a small extent of residual inhibition, which is completely blocked by the CS- E antibody. These results suggest that CS-E protein interactions play an important role in the CS-E signaling pathway and selective intervention of this pathway is able to block the inhibitory effects of CS-E polysaccharides and promote neurite outgrowth. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth.
Example 5: Carbohydrate microarray assays
[00143] Carbohydrate microarray assays are useful for screening for or identifying binding agents that selectively bind one or more carbohydrates including but not limited to polysaccharides such as proteoglycans including CSPGs such as CS-A, CS-C, or CS-E. Carbohydrate microarrays are generated by spotting approximately 1 nL of heparin (Sigma), hyaluronic acid (Sigma), dermatan sulfate (Sigma), heparan sulfate (Neoparin), chondroitin (Seikagaku), chondroitin sulfate (Seikagaku), or keratan sulfate (Seikagaku) polysaccharide solutions onto poly-L-
lysine-coated slides using a Microgrid II arrayer (Biorobotics; Cambridge, UK) at room temperature and 50% humidity. The concentrations of the solutions range from 250 nM to 40 μM, and are calibrated to one another using the carbazole assay for uronic acid residue. A given concentration of each polysaccharide is spotted five to ten times at different positions on the array. A boundary is created around the polysaccharide spots on the slides using a hydrophobic slide marker (Super Pap Pen, Research Products International) and the slides are blocked with 5-10% fetal bovine serum (FBS) in PBS with gentle rocking at 37 0C for about 1 hr, followed by a brief rinse with PBS. Human NgR-Fc or mouse EphB2-Fc (R & D Systems) is reconstituted in 1% BSA in PBS, added to the bound region on the slides in 100 μl quantities at a concentration of 1-2 μM, and incubated at room temperature for about 3 hr. The slides are briefly rinsed three times with PBS, and then incubated with a goat anti-human IgG antibody conjugated to Cy3 (1:5000 in PBS) for 1 hr in the dark with gentle rocking. After rinsing two times with PBS and once with H2O, the microarray is analyzed at 532 nm using a GenePix 5000a scanner, and fluorescence quantification is performed using GenePix 6.0. Binding of the anti-CS-E antibody is evaluated using 100 μl of a 1 μg/ml (~7 nM) solution of antibody and a goat anti-mouse IgG secondary antibody conjugated to Cy3 (1:5000 in PBS). Under the conditions described herein, the results show that the compositions of the present invention are selective binders of one or more of CS-A, CS-C, or CS-E.
[00144] In one example, Ephrin receptor family proteins were screened for binding to CS-E-enriched polysaccharides. The binding of proteins EphAl, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7 and EphA8 were examined relative to binding to Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 μM (Figure 15).
Results from this example demonstrate that EphA4 selectively binds to CS-E-enriched polysaccharides.
[00145] In another example, Ephrin family proteins, a large family of protein ligands that activate Eph receptors, were screened for binding to CS-E-enriched polysaccharides. The binding of proteins EfnAl, EfnA2, EfnA3, EfnA4, EfnA5, EfnBl, EfnB2, and EfnB3 were examined relative to binding to Chondroitin, CS-A, CS-C, CS-D, CS-E, Dermatan Sulfate, Heparan Sulfate, Heparan, and Hyaluronic Acid at varying polysaccharide concentrations of 0.5, 1, 5, and 20 μM (Figure 16). Results from this example demonstrate that EfnA3 and EfnBl selectively bind to CS-E-enriched polysaccharides.
[00146] In another example, competition assays were utilized in the context of the carbohydrate microarray assay. In the competition binding example described, these results demonstrate that CS-E antibody can compete for binding of Nogo Receptor (NgR) to CS-E polysaccharides on carbohydrate arrays (Figure 18). In Figure 18A, the CS-E antibody blocks binding of NgR-Fc to CS-E on the array. The binding reagents mixed are: NgR alone (20OnM, left), NgR and CSE- Ab (20OnM and 10 μM, respectively, middle) or CS-E Ab alone (10 μM, right). CS-E antibody competition for CS-E binding to NgR demonstrate specific binding of CS-E to NgR. In addition, it suggests the importance of CS-E interactions with NgR in the CS-E signaling cascade.
Example 6: Oligosaccharide microarray assays
[00147] Oligosaccharide microarray assays are useful for screening for or identifying binding agents that selectively bind one or more carbohydrates including but not limited to polysaccharides such as proteoglycans including CSPGs such as CS-A, CS-C, or CS-E. Immobilization of oligosaccharides may be performed by conjugation of oligosaccharides to l,2-(bisaminooxy)ethane. Ozonolysis of the anomeric allyl group and linkage of CS compounds 1-41,2 to l,2-(bisaminooxy)ethane3 proceeds as follows: oligosaccharide (0.51 μmol) is dissolved in MeOH (500 μL) and cooled to -78 0C. O3 is bubbled through the reaction until a blue color persists (1 min). The
reaction is then purged with N2 until colorless, quenched with Ph3P beads (3 mg), and gradually warmed to rt over 12 h. The reaction is filtered and the product concentrated to afford the desired aldehyde as a white solid. The aldehyde (0.51 μmol) is then reacted for 14 h at rt with l,2-(bisaminooxy)ethane hydrochloride (1.4 mg, 15 umol) that has been dissolved in H2O (100 μL) and pH adjusted to 5.0 with 1 M NaOH. The resulting oxime product is purified using a SepPak Cl 8 column (500 mg, H2O) and Sephadex G-IO (CS-E disaccharide, H2O) or Sephadex G- 25 (tetrasaccharides, H2O) to afford a white solid in quantitative yield (0.51 μmol). CS-A aminooxy: ESI MS: m/z: calculated for C32H48N4Na3O3IS2: 1117.1; found 1117.0. CS-C aminooxy: ESI MS: m/z: calculated for
C32H48N4Na3O3IS2: 1117.1; found 1117.0. CS-E aminooxy: ESI MS: m/z: calculated for C32H46N4Na5O37S4: 1321.0; found 1321.0. CS-E di amminooxy: ESI MS: m/z: calculated for C18H28N3Na2O20S2: 716.1; found 716.0. Mass spectra are obtained on a PerkinElmer/Sciex API 365 triple quadrupole/electrospray tandem mass spectrometer in the Protein/Peptide MicroAnalytical Laboratory at the California Institute of Technology.
[00148] The relative concentrations of the aminooxy oligosaccharides are calibrated to one another using the carbazole assay for uronic acid residues. Briefly, the acid borate reagent (1.5 mL of 0.80 g sodium tetraborate, 16.6 mL H2O, and 83.3 mL H2SO4) is added to 20-mL glass vials with Teflon caps. The aminooxy
oligosaccharides (50 μL of a 0.2 mg/mL stock in H2O) are added and the solution placed in a boiling H2O bath for 10 min. Following addition of the carbazole reagent (50 μL of 0.1% w/v carbazole in 100% EtOH), the solution is boiled for 15 min. The absorbance is read at 530 nm and compared to a D-glucuronolactone standard in H2O.
[00149] Solutions of the aminooxy oligosaccharides (in 300 mM NaH2PO4, pH 5.0, 10 μL/well in a 384- well plate) are arrayed on Hydrogel Aldehyde slides (NoAb Biodiscoveries) using a Microgrid II arrayer
(Biorobotics) to deliver sub-nanoliter volumes at rt and 50% humidity. Concentrations of carbohydrates range from 0- 500 μM. The resulting arrays are incubated in a 70% humidity chamber at rt for 12 h and then stored in a low humidity, dust-free dessicator. The pH and reaction time are optimized to provide maximum immobilization of the compound. Non-specific attachment of CS oligosaccharides lacking the aminooxy linker (e.g., compounds 1-4) is not observed. Prior to use, the arrays are outlined with a hydrophobic pen (Super Pap Pen, Research Products International) to create a boundary for the binding agent treatments and rinsed three times with H2O. The slides are then blocked by treatment with NaBH4 (125 mg) in 140 mM NaCl, 2.7 mM KCl, 5.4 mM Na2HPO4, and 1.8 mM KH2PO4 (phosphate buffered saline, PBS, 50 mL) at rt for 5 min with gentle rocking and washed five times for 3 min with PBS. For all incubations, the slides are placed in a covered pipette tip box. Human TNF-α (Peprotech), FGF-I (R&D Systems; both reconstituted to 2 μM in 0.1% Triton X-IOO in PBS), cell culture supernatant containing monoclonal anti-CS-A antibody, or cell culture supernatant containing monoclonal anti-CS-E antibody (both 1:1 in 0.1% Triton X-IOO in PBS) are spotted onto the slides in 250 μL quantities, and incubated statically at rt for 2 h. The slides are then washed as previously described and incubated with the appropriate primary antibody [anti-TNF-α (Peprotech) or anti-FGF-1 (R&D Systems); 1:1000 in 0.1% Triton X-IOO in PBS] for 2 h at rt with gentle rocking. Following the incubation, the slides are washed as previously described and treated in the dark at rt with a secondary IgG antibody conjugated to Cy3 (Amersham; 1:5000 in 0.1% Triton X-100 in PBS) at rt for 1 h with gentle rocking. The slides are washed three times for 2 min with PBS, two times for 1 min with H2O, and dried under a gentle stream of N2. Microarrays are analyzed at 532 nm using a GenePix 5000a scanner, and fluorescence quantification is performed using GenePix 6.0 software after correction for local background. Each binding agent is analyzed in triplicate, and an average fluorescence intensity of at least five spots for a given carbohydrate concentration is observed. All solutions used for the carbohydrate microarrays are sterile-filtered
through a 0.2 μm syringe filter prior to use. Under the conditions described herein, the results show that the compositions of the present invention are selective binders of one or more of CS-A, CS-C, or CS-E.
Example 7: ELISA assay
[00150] ELISA assays can be used for detecting protein binding to a receptor or substrate, detecting the presence of a protein or carbohydrate, quantifying protein expression, or quantifying protein activity. ELISA assays can also be used for identifying agents that disrupt the binding between CS and a known binding partner. Antigens are absorbed on Nunc Maxisorp 384-well plates. For CSPG binding assays, CSPGs (at approximately 10 μg/ml; in about 25 μl) are incubated in each well for about 2 hr. For CS binding assays, streptavidin (at approximately 20 μg/ml; in about 50 μl) is absorbed in each well for about 1 hr, followed with biotinylated CS (at approximately 20 μg/ml; in about 50 μl) for about 1 hr. After blocking with 1-10% BSA in PBS, the anti-CS-E antibody
(approximately 25 μl of 20 μg/ml or indicated concentrations in 1-3% BSA in PBS) is incubated in each well for about 2 hr. Following incubation with horseradish peroxidase-conjugated anti-mouse IgG secondary antibody, the plate is developed with TMB substrate (3,3 ',5,5 '-tetramethylbenzidine; Pierce) for about 20 min and quenched with 1-3M H2SO4. The absorption at 450 nm is recorded on a PerkinElmer Victor plate reader. Experiments are repeated in triplicate, and data representing the average values (± SD, error bars) are reported for one representative experiment. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at inhibiting CS-E mediated signaling.
Example 8: Pull-down assays with biotinylated CS
[00151] Pull down assays can be useful for identifying proteins which bind to CS (e.g. CS-A, CS-C, or
CS-E). Pull down assays can also be used for identifying agents that disrupt the binding between CS and a known binding partner. Full-length human p75 cDNA (amino acids 1-427; Open Biosystems) is ligated into a pcDNA3 vector (Invitrogen), modified to fuse an HA tag to the 5' end of the insert. Human NgR (amino acids 27-473; imaGenes) is ligated into a modified pAPtag-5 vector (GenHunter) which fuses a secretion signal sequence and a c- myc tag to the 3 ' end of the insert. COS-7 cells are transfected with either NgR-myc, p75-HA, or both using the Lipofectamine (Invitrogen) method. Cells are lysed about 2 days after transfection with 0.5-2% Triton X-100 in PBS containing a protease inhibitor mixture (Roche) by rocking for 15-90 min at 4 0C. The lysates are clarified by centrifugation at 5-25,000 rpm for 1-30 min.
[00152] Biotin is attached to the free amino group of the residual core peptides of CS-C and CS-E polysaccharides (Seikagaku). Briefly, CS-C and CS-E (about 2 mg each) are dissolved in about 1 mL of 0.015-0.1 M NaHCO3 for about 30 min at room temperature. EZ-Link Sulfo-NHS-LC-LC-Biotin (approximately 0.25 mg; Pierce) is dissolved in about 1 mL OfH2O and added to each CS sample. The solution is mixed at room temperature for about 1-10 hr, lyophilized, resuspended in H2O, and subjected to gel filtration using Sephadex G-50 or G-25 (Amersham) to remove excess biotin.
[00153] Biotinylated CS-C or CS-E (approximately 280 μg each) in 100-500 μl of PBS is added to streptavidin agarose resin (about 140 μl; Pierce) and incubated at room temperature for about 1 hr. The supernatant is removed, and the resin washed 1-5 times with about 500 μl of PBS to remove unconjugated CS. Clarified COS-7 cell lysates are diluted 1:5 to 1:20 with PBS, and further diluted approximately 1:2 with H2O. Diluted lysate (about 500 μl, corresponding to approximately 0.8 mg/ml total protein) is precleared by incubation with unconjugated streptavidin agarose resin (e.g. 30 μl) with mixing for about 1 hr at 4 0C. The supernatant is collected, added to either CS-C or CS-E streptavidin agarose resin (e.g. 30 μl), and incubated with mixing for about 4 hr at 4 0C. The
supernatant is removed, and the resin is washed 1-5 times with about 500 μl PBS. Resin is boiled with about 30 μl of 2X loading dye (100 mM Tris, 200 mM DTT, 4% SDS, 0.10% bromophenol blue, 20% glycerol), and the eluates are collected and separated by SDS-PAGE. NgR-myc and p75-HA are detected by immunoblotting with myc-tag (Cell Signaling) or HA-tag (Sigma) antibodies. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at inhibiting the binding of CS-E to NgR, p75NTR, or other binding partners of CS-E including but not limited to Nogo, OMgp, and Ephrin B3 receptor.
Example 9: Surface plasmon resonance
[00154] Surface plasmon resonance experiments can be used to provide quantitative measurements of the binding kinetics or affinity between two or more molecules such as proteins, peptides, and small molecules. All experiments are performed on a Biacore TlOO at 25 0C using a Sensor Chip CM5 with a running buffer composed of 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% Surfactant P20 (HBS-EP+). To analyze the binding of anti-CS-E antibody to the CS-E tetrasaccharide, both control and active flow cells are exposed to a 1:1 mixture of N- hydroxysuccinimide (NHS) and l-ethyl-S^-dimethylaminopropyl-carbodiimide (EDC) for 1-10 min at a flow rate of about 10 μL-mkf1. Next, 1-10 mM carbohydrazine is injected at the same flow rate for about 5-15 min. Ligand is covalently attached to the surface by injecting a 0.1-1 mM solution of synthetic CS-E tetrasaccharide bearing an aldehyde group on a reducing-end linker, onto the active flow cell briefly at a high flow rate (approximately 10 s, 60 μL-min"1), followed by a 20 min injection of 0.1 M sodium cyanoborohydride in 0.1 M sodium acetate pH 4.0 at about 2 μL-mkf1. Because of the low molecular weight of the CS-E tetrasaccharide, it may be difficult to observe the amount of ligand bound to the surface. Instead, approximately 500 nM of anti-CS-E antibody is injected into both the control and active flow cell to test the response. The amount of ligand is increased accordingly until an adequate response is observed. The kinetics of the anti-CS-E antibody/CS-E tetrasaccharide interaction is determined by approximately 300 s long injections of anti-CS-E antibody at about 30 μL-mirf \ The dissociation is monitored for about 900 s before the surface is regenerated with a 30 s injection of 6 M guanidine HCl. The resulting sensorgrams are fit to the bivalent analyte model. Affinity analysis is measured by injecting the antibody for about 3600 s at 5 μL-mirT \ After 3600 s, the surface is regenerated with a 60 s injection at about 10 μL-mirf \ The data is analyzed by plotting the response at equilibrium versus concentration and fitting the resulting curve to the Langmuir equation.
[00155] For the NgR interaction with CS-E-enriched polysaccharides, all flow cells are activated with
NHS and EDC following the manufacturer's amine coupling protocol. Streptavidin (at approximately 1 μM, 0.01 M NaOAc, pH 5.0) is conjugated to the activated surfaces until saturation, followed by ethanolamine blocking.
Biotinylated CS-E, composed of -61.5% of the CS-E disaccharide motif, the remainder of which is a mixture of CS- A, CS-C, and unsulfated disaccharides, is immobilized to flow cell 2 to give an RL of 25 response units (RU); biotinylated CS-C is immobilized to flow cell 4 to give a similar RL. Flow cells 1 and 3 are used as controls to subtract bulk response. NgR-Fc is passed over the surface at 25 0C with a flow rate of about 80 μL-mkf1 for 240 s, and the dissociation monitored for 600 s. The surface is regenerated by three injections of 90 s of 2.5 M MgCl2 at 30 μL-mirT \ NgR-Fc injection results in binding of NgR-Fc to CS-E polysaccharides with two apparent kinetic processes, presumably caused by variations in the density of CS-E motifs along the polysaccharide chain. No binding is detected to CS-C-enriched polysaccharides. The resulting sensorgrams are analyzed using Biacore TlOO evaluation software V2.0 and fit to the heterogeneous ligand model with the value of bulk refractive index (RI) set to zero. Under the conditions described herein, the results show that the methods and compositions of the present
invention are effective at selectively binding to CS-E. The assay further shows that NgR and p75 bind to CS-E but not CS-C.
[00156] In another example, utilizing the surface plasmon resonance methods described, data was generated to quantify measurements of the binding kinetics between CS-E and the binding partner EphA4. The results show (Figure 15, bottom) that EphA4 binds to CS-E-enriched polysaccharides with a dissociation constant
(Kd) of 699nM, demonstrating a strong binding affinity and suggesting that EphA4 may be an important target for
CS-E-enriched polysaccharides.
[00157] In another example, utilizing the surface plasmon resonance methods described, data was generated to quantify measurements of the binding kinetics between CS-E and the binding partner EfnA3. The results show that EfnA3 binds to CS-E-enriched polysaccharides with a dissociation constant (Ka) of 65nM, demonstrating a strong binding affinity and suggesting that EfnA3 may be an important target for CS-E-enriched polysaccharides.
[00158] In another example, utilizing the surface plasmon resonance methods described, data was generated to quantify measurements of the binding kinetics between CS-E and the binding partner EfnBl . The results show (Figure 16, bottom) that EfnBl binds to CS-E-enriched polysaccharides with a dissociation constant
(Kd) of 138nM, demonstrating a strong binding affinity and suggesting that EfnBl may be an important target for
CS-E-enriched polysaccharides.
[00159]
Example 10: Immunostaining of retinal and optic nerve sections
[00160] Histochemical staining of retinal and optic nerve sections can be used to assess nerve growth, neurite outgrowth, growth cone collapse, neuron survival, and neuronal regeneration. At 1-14 days post injury, mice are given an overdose of pentobarbital and are transcardially perfused with 4% PFA. Eyeballs still attached with the optic nerve are dissected and post-fixed in 4% PFA overnight. Following cryoprotection with 30% sucrose in PBS, tissues are embedded in O.C.T. and serial sectioned for 5-20 μm along the longitudinal direction of the nerve. For immunofluorescence labeling, the sections are washed with PBS, pre-incubated in a blocking buffer (approximately
1% BSA, 0.3%TX-100 in PBS) and followed by sequential incubations with primary antibodies, including mouse anti-CS-E (1:200), goat-anti-CTB (1:4000), or rabbit anti-βlll-tubulin antibodies (Invitrogen). The sections are then reacted with biotinylated anti-goat IgG (1:200) and visualized with Alexa Fluor 546-conjugated streptavidin (1:400) or with a Cy3 -conjugated goat anti-mouse or -rabbit IgG. The retinal cryosections are mounted with Vectashield and visualized under a Nikon fluorescence microscope. To quantify the number of CTB-positive regenerating axons, the number of regenerating axons is counted at 125 μm stepwise from the crush site of the optic nerve. The total number of regenerating axons is estimated. To quantify the number of surviving retinal ganglion cells, the total number of βlll-tubulin positive cells is counted in at least 3 retinal sections per retina. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth, nerve growth, neuron survival, and neuronal regeneration, and are also effective at inhibiting growth cone collapse.
Example 11: Optic nerve regeneration assay
[00161] The optical nerve regeneration assay can be used to asses nerve growth, neurite outgrowth, growth cone collapse, neuron survival, and neuronal regeneration. Immediately after crush injury in the optic nerve of adult mice, gelfoam that has been soaked in a solution containing control IgG, anti-CS-E antibody (1.7 mg/ml),
chondroitinase ABC (chABC; 50 U/ml), or chABC (50 U/ml) plus anti-CS-E (1.7 mg/ml) antibody is placed around the crush site of the nerve and replaced at day three and six after injury. In other groups of mice, mice that received an intravitreal injection of CPT-cAMP (100 mM, 2 μl) alone or CPT-cAMP plus anti-CS-E (1.7 mg/ml) antibody treatment placed around the crush site of the nerve are studied. To label retinal ganglion cell axons, 2 μl of a solution containing an anterograde axon tracer, CTB, is injected intravitreally 3 days before mice were sacrificed. The extent of axonal regrowth is assessed 2 weeks after injury. Under the conditions described herein, the results show that the methods and compositions of the present invention are effective at promoting neurite outgrowth, nerve growth, neuron survival, and neuronal regeneration, and are also effective at inhibiting growth cone collapse.
Example 12: Axon regeneration and motor function recovery assay in mice
[00162] The axon regeneration and motor function assay in mice can be used to assess the efficacy of the methods and compositions of the present invention in promoting the enhancement of locomotor function, bladder function, neuromuscular functional recover or walking in a subject.
[00163] Surgical methods: For surgery, mice are anesthetized with an IP injection of Avertin. Hair is removed by shaving, and the skin is treated with betadine. A midline incision is made over cervical spinous processes and paravertebral muscles are separated from the vertebrae. A laminectomy is performed at T8 or C5. Dorsal hemisections are performed using a Moria micro knife. After producing the spinal cord injuries, the muscle is sutured in layers, and the skin is closed with wound clips. Post-operatively, animals receive saline, dextrose, Baytril, and Buprenorphine subcutaneously and are placed on a warming blanket at 37°C overnight. Bladders are manually expressed for the first week.
[00164] Assessing hindlimb motor function after T8 lesions: Hindlimb motor function during locomotion is assessed at 2, 7, 14, 21, 28, 35, and 42 days post-injury using the BBB and BMS scales. Kinematic analyses are carried out at 22 and 43 days; hindlimb placement on a horizontal ladder with variably spaced rungs is be assessed at 20 and 40 days post-injury.
[00165] Measuring forepaw function after C5 lesions using a grip strength meter: Forepaw grip strength is repeatedly measure over time in mice and rats using a Grip Strength Meter distributed by SciPro, Inc. The task takes advantage of the natural tendency of mice to reach out and grasp nearby objects. In brief, mice are handled and trained until they became accustomed to having one paw restrained with tape. The tape prevents that foot from being used to grasp the bar so that grip strength can be measured independently for each paw. For testing, mice are held by the base of the tail close to the bar of the grip strength meter, which they grasp with the free paw. The mice are pulled gently away until they release their grip, and the device measures the maximal force exerted before the paw releases its grip. This task offers considerable advantages because maximal grip strength is remarkably consistent from animal to animal and over prolonged periods of repeated testing.
[00166] Assessing corticospinal tract (CST) regeneration/sprouting: Regenerative growth of CST axons is assessed as described herein using histochemical staining methods. Under the conditions described herein, the methods and compositions of the present invention can be effective at promoting CST regeneration.
Example 13: CS mediated Rho activation assay
[00167] The Rho activation assay can be used to assay for inhibitors of CS mediated Rho activation.
Transfected COS-7 cells are treated with CS-E in combination with Nogo, OMgp or no protein, and RhoA-GTP levels are measured using methods known in the art (See e.g., Nature Neuroscience 7, 221-228 (2004); Neuron 45, 353-359 (2005); and Journal of Cell Biology 157, 565-570 (2002)). Briefly, the RhoA-binding domain of the
effector protein Rhotekin can be used to affinity precipitate the GTP-bound form of RhoA. The amount of precipitated GTP -RhoA can then be determined for example by blotting or ELISA. RhoA activation levels are compared to those obtained using Nogo or OMgp alone. The results of these assays demonstrate that the methods and compositions of the present invention are effective at inhibition of CS mediated signaling.
Example 14: Cortical legion immunostaining assay
[00168] Observing the increased expression of a protein in response to neural injury further emphasizes its importance in the tissue response signaling chain of events. In one example, expression of the CS-E motif was assessed after brain injury in vivo in rats as described herein using histochemical staining methods. Sections from rat brains with cortical lesions at 1 day, 3 days, and 7 days post lesion were immunostained with the CS-E antibody. Increased immunostaining around the lesion was observed at all three time points, and levels of staining appeared highest at 3 days post-lesion. At 1 day post lesion, there was a diffuse increase in immunostaining confined to the region immediately adjacent to the lesion. There was staining of cells throughout the brain and a few cells near the lesion exhibited higher levels of punctate staining. At 3 days post lesion, levels of staining around the lesion appeared higher, and the general cellular staining throughout the brain seemed a bit more intense. By 7 days post- lesion, the staining decreased at the lesion and throughout the brain.
[00169] Immunostaining was also assessed 2 days following a dorsal funiculus lesion of the rat spinal cord. As with cortical lesions, there was a general increase in immunostaining in the lesion margin, and some cells around the lesion expressed CS-E at a fairly high level. Some cells in the gray matter also stained for CS-E, but not as intensely as those near the lesion. Dorsal and ventral white matter also stained for CS-E in a pattern that resembled neurofilament expression.
[00170] Together, these data demonstrate that the CS-E sulfation motif is upregulated shortly after brain or spinal cord injury in vivo. These findings also suggest that the time course for treating with the CS-E antibody should likely be early, given the rapid increase in CS-E expression within 1-2 days post injury.
[00171] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1. A method of promoting neuronal regeneration in a subject, comprising: administering to said subject in need thereof a pharmaceutical composition comprising a physiologically acceptable carrier and an agent that inhibits chondroitinsulfate-E (CS-E) signaling, wherein said agent is present in an amount effective in promoting neurite outgrowth in said subject.
2. The method of claim 1, wherein the agent is a chondroitin- sulfate -E (CS-E) binding agent.
3. A method of treating a subject suffering from a neural injury, comprising: administering to said subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a chondroitin- sulfate -E (CS-E) binding agent and a physiologically acceptable carrier.
4. A method of reducing chondroitin sulfate proteoglycan (CSPG)-mediated inhibition of neuronal growth, comprising: contacting a biological sample comprising extracellular matrix components with a chondroitinsulfate-E (CS-E) binding agent under conditions sufficient to reduce CS-E-signaling in said neuronal cell.
5. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent is an antibody that binds selectively to CS-E.
6. The method of claim 5, wherein said antibody is a monoclonal antibody.
7. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent is soluble protein that binds selectively to CS-E.
8. The method of claim 7, wherein the soluble protein comprises a domain of p75, NgR, Nogo, OMgp, or Eph receptor B3 that selectively binds to CS-E.
9. The method of claim 7, wherein the soluble protein comprises a domain of Ephrin A3, Eph receptor A4, or Ephrin Bl each of which selectively binds to CS-E.
10. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent inhibits CS-E signaling as evidenced by inhibition of activation of RhoA in a neuronal cell or a cell expressing p75NTR, or inhibition of binding of CS-E to a surface of a neuronal cell or a cell expressing p75NTR.
11. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent inhibits CS-E-mediated neuronal growth cone collapse.
12. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent promotes neurite outgrowth in vitro.
13. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent exhibits a binding affinity as measured in Kd value of about 50 nM or less in an in vitro binding assay.
14. The method of any one of claims 2-4, wherein said administration of chondroitin-sulfate-E (CS-E) binding agent results in an enhancement of locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in said subject.
15. The method of any one of claims 2-4, wherein the chondroitin-sulfate-E (CS-E) binding agent is administered within 1 to 2 days post injury.
16. The method of any one of claims 1 -3 wherein the subject has suffered from an injury selected from the group consisting of spinal cord injury, optic nerve injury, motor nerve injury, stroke, and a combination thereof or a neurodegenerative disease.
17. The method of claim 1, wherein the chondroitin-sulfate-E (CS-E) signaling comprises intracellular signaling mediated by one or more cellular proteins selected from the group consisting of MEK, epidermal growth factor receptor (EGFR), protein kinase C (PKC), rho kinase (RhoK), and RhoA.
18. A pharmaceutical composition comprising a chondroitin-sulfate-E (CS-E) binding agent and a physiologically acceptable carrier.
19. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is an antibody exhibiting binding selectively to CS-E.
20. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is a monoclonal antibody exhibiting binding selectively to CS-E.
21. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is soluble protein exhibiting binding selectively to CS-E.
22. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of NgR that selectively binds to CS-E.
23. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of p75 that selectively binds to CS-E.
24. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of Nogo, OMgp, or Eph receptor B3 that selectively binds to CS-E.
25. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent is a soluble protein exhibiting binding selectively to CS-E, wherein the soluble protein comprises a domain of Ephrin A3, Eph receptor A4, or Ephrin Bl each of which selectively binds to CS-E.
26. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent inhibits CS-E signaling as evidenced by inhibition of activation of RhoA in a neuronal cell or a cell expressing p75NTR, or inhibition of binding of CS-E to a surface of a neuronal cell, or a cell expressing p75NTR.
27. The pharmaceutical composition of claim 18, wherein the chondroitin-sulfate-E (CS-E) binding agent promotes neurite outgrowth in vitro.
28. The pharmaceutical composition of claim 18, wherein said administration of chondroitin-sulfate-E (CS-E) binding agent results in an enhancement of locomotor function, grasping, bladder function, neuromuscular functional recovery, or walking in said subject.
29. The use of an agent that inhibits chondroitin-sulfate-E (CS-E) signaling for the manufacturing of a medicament for promoting neuronal regeneration, wherein said agent promotes neurite outgrowth in a subject in need of such medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10803019.8A EP2456456A4 (en) | 2009-07-24 | 2010-07-26 | Methods and compositions for treating neuronal damage or degeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27170509P | 2009-07-24 | 2009-07-24 | |
US61/271,705 | 2009-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011011789A1 true WO2011011789A1 (en) | 2011-01-27 |
Family
ID=43497508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/043256 WO2011011789A1 (en) | 2009-07-24 | 2010-07-26 | Methods and compositions for treating neuronal damage or degeneration |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110020359A1 (en) |
EP (1) | EP2456456A4 (en) |
WO (1) | WO2011011789A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
JP6659024B2 (en) * | 2014-03-31 | 2020-03-04 | 生化学工業株式会社 | Anti-chondroitin sulfate E antibody |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5959094A (en) * | 1994-05-11 | 1999-09-28 | Yeda Research And Development Co. Ltd. | p75 TNF receptor promoters |
US20070044161A1 (en) * | 2005-07-21 | 2007-02-22 | Juergen Soutschek | RNAi modulation of the Rho-A gene in research models |
US20070275412A1 (en) * | 2006-05-22 | 2007-11-29 | California Institute Of Technology | Chondroitin sulfate binding proteins and modulators thereof |
US20080009607A1 (en) * | 2006-05-22 | 2008-01-10 | California Institute Of Technology | Antibodies to sulfated carbohydrates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1534736E (en) * | 2002-08-10 | 2010-09-07 | Univ Yale | Nogo receptor antagonists |
-
2010
- 2010-07-26 US US12/843,758 patent/US20110020359A1/en not_active Abandoned
- 2010-07-26 EP EP10803019.8A patent/EP2456456A4/en not_active Withdrawn
- 2010-07-26 WO PCT/US2010/043256 patent/WO2011011789A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5959094A (en) * | 1994-05-11 | 1999-09-28 | Yeda Research And Development Co. Ltd. | p75 TNF receptor promoters |
US20070044161A1 (en) * | 2005-07-21 | 2007-02-22 | Juergen Soutschek | RNAi modulation of the Rho-A gene in research models |
US20070275412A1 (en) * | 2006-05-22 | 2007-11-29 | California Institute Of Technology | Chondroitin sulfate binding proteins and modulators thereof |
US20080009607A1 (en) * | 2006-05-22 | 2008-01-10 | California Institute Of Technology | Antibodies to sulfated carbohydrates |
Non-Patent Citations (4)
Title |
---|
DEWITT ET AL.: "Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases", BRAIN RESEARCH, vol. 656, 1994, pages 205 - 209, XP024283166 * |
RHODES ET AL.: "Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?", J. ANAT., vol. 204, 2004, pages 33 - 48, XP008148859 * |
See also references of EP2456456A4 * |
YIU ET AL.: "Glial inhibition of CNS axon regeneration.", NAT REV NEUROSCI., vol. 7, no. 8, 2006, pages 617 - 627, XP008148871 * |
Also Published As
Publication number | Publication date |
---|---|
EP2456456A4 (en) | 2013-11-20 |
EP2456456A1 (en) | 2012-05-30 |
US20110020359A1 (en) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11999779B2 (en) | Anti-complement factor C1q Fab fragments and uses thereof | |
EP1910829B1 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
JP3981148B2 (en) | Axon regeneration promoter | |
US20150203585A1 (en) | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System | |
KR102105436B1 (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
US20190161535A1 (en) | Compositions and methods for treating spinal muscular atrophy | |
WO2008063849A9 (en) | Multiple sclerosis therapy | |
KR20080081069A (en) | Materials and methods for treating chronic fibrotic diseases | |
CA3030872A1 (en) | Compositions and methods for treating frontotemporal dementia | |
US20180201676A1 (en) | Methods and compositions for modulating lilr proteins | |
CN118021970A (en) | Antagonists of the complement system for methods of treating paraproteinemic neuropathy | |
AU2023200728A1 (en) | Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized | |
US20110020359A1 (en) | Methods and compositions for treating neuronal damage or degeneration | |
RU2350623C2 (en) | ANTI-Nogo ANTIBODIES ("11C7") AND THEIR APPLICATION IN PHARMACEUTICS | |
EP3454902A1 (en) | Anti-complement factor c4/c4b antibodies and uses thereof | |
US20170007633A1 (en) | TREATMENT OF NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES BY INHIBITION OF THE a2-Na/K ATPase/a-ADDUCIN COMPLEX | |
US20150139981A1 (en) | Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica | |
EP4206229A1 (en) | A binding molecule able to neutralize proxi protein | |
BRPI0818928B1 (en) | ISOLATED NOGO-A BINDING MOLECULES, THEIR PRODUCTION METHOD AND USE, ISOLATED POLYNUCLEOTIDE, VECTOR AND EXPRESSION SYSTEM, ISOLATED HOST CELL, AND PHARMACEUTICAL COMPOSITION | |
WO2008059959A1 (en) | Nerve elongation promoter and elongation inhibitor | |
WO2017028782A1 (en) | Application of brain-derived neurotrophic factor precursor protein as target spot for treating affective disorders | |
CN111093684A (en) | Compositions and methods for treating myelin disorders | |
US11891447B2 (en) | Method for treating cancer using CD14 antagonists | |
JPWO2006006337A1 (en) | Drugs for preventing or treating neurological diseases | |
CN116854815A (en) | Modified antibodies targeting amyloid and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10803019 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2010803019 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010803019 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |